NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

  • By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.
Cover of Holland-Frei Cancer Medicine

Holland-Frei Cancer Medicine. 6th edition.

Show details

Chapter 92References

, MD, , MD, , MD, PhD, , MD, and , MD.

1.
Hoover R. Epidemiology: tobacco and geographic pathology. In: Harris CC, editors. Pathogenesis and therapy of lung cancer. New York: Marcel Dekker; 1978. p. 3–24.
2.
Hoffmann D, Hecht SS. N'-nitrosonornicotine in tobacco. Science. 1974;186:265–7. [PubMed: 4414773]
3.
Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64:235–48. [PubMed: 1988146]
4.
Jemal A, Murray T, Samuels A. et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. [PubMed: 12568441]
5.
Ochsner A, DeBakey M. Carcinoma of the lung. Arch Surg. 1941;42:209–58.
6.
US Department of Health & Human Services. The health consequences of smoking: nicotine addiction: a report of the Surgeon General. USHHS 1988;CDC #88–8406.
7.
American Cancer Society. Cancer facts and figures. Washington, DC:ACS 1995.
8.
Shopland DR, Eyre HJ, Pechacek TF. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst. 1991;83:1142–8. [PubMed: 1886147]
9.
Wynder EL, Hoffman D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res. 1994;54:5284–95. [PubMed: 7923155]
10.
Johnston LD, Bachman JG, O'Malley PM. Twentieth national survey of American high school seniors and the fourth national survey of eighth and tenth grade students (Press Release). University Of Michigan. 1995.
11.
National Institute of Health. Respiratory health effects of passive smoking: lung Cancer and other disorders. NCI Monograph 1993;4.
12.
Peto R. Influence of dose and duration of smoking on lung cancer rates. Tobacco: a major international health hazard. Proc IARC ; 23–24. 1986.
13.
O'Rourke MA, Feussner JR, Feigl P. et al. Age trends of lung cancer stage at diagnosis: implications for lung cancer screening in the elderly. JAMA. 1987;258:921–6. [PubMed: 3613022]
14.
Sherman S, Guidot CE. Feasibility of thoracotomy for lung cancer in the elderly. JAMA. 1987;258:927–30. [PubMed: 3449075]
15.
Miller JI Jr. Physiologic evaluation of pulmonary function in the candidate for lung resection. J Thorac Cardiovasc Surg. 1993;105:347–51. [PubMed: 8429663]
16.
Osborne DR, Korobkin M, Ravin CE. et al. Comparison of plain radiography, conventional tomography, and computed tomography in detecting intrathoracic lymph node metastases from lung carcinoma. Radiology. 1982;142:157–61. [PubMed: 7053525]
17.
Travis WD, Travis LB, Devesa SS. Lung cancer incidence and survival by histologic type. Cancer. 1995;75:191–202. [PubMed: 8000996]
18.
Sugimura R, Watanabe S. Case-control study on histologically determined multiple primary lung cancer. J Natl Cancer Inst. 1987;79:435–41. [PubMed: 3476786]
19.
Mountain CF, Lukeman JM, Hammar SP. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol. 1987;35:147–56. [PubMed: 3037195]
20.
Gail MH, Eagan RT, Feld R. et al. Prognostic factors in patients with resected stage I non-small-cell lung cancer. Cancer. 1984;54:1802–13. [PubMed: 6478416]
21.
Shield TW, Yee J, Conn JH. et al. Relationship of cell type and lymph node metastases to survival after resection of bronchial carcinoma. Ann Thorac Surg. 1975;20:501–10. [PubMed: 172035]
22.
Nagasaki R, Flehinger B, Martini N. et al. Complications of surgery in the treatment of carcinoma of the lung. Chest. 1982;82:25–9. [PubMed: 7083931]
23.
Read RC, Schaefer R, North N. et al. Diameter, cell type, and survival in stage I primary non-small-cell lung cancer. Arch Surg. 1988;123:446–9. [PubMed: 2831849]
24.
Feld R, Rubinstein L, Weisenburger T. et al. Site of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol. 1984;2:1352–7. [PubMed: 6512581]
25.
Zhang L. Results of surgical treatment of stage I non-small-cell lung cancer. Chung Hua Chung Liu Tsa Chih. 1993;115:209–11. [PubMed: 8261868]
26.
Kadri MA, Dussek JE. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma. J Natl Cancer Inst. 1991;79:435–9.
27.
Luketich JD, Ginsberg RJ. Limited resections versus lobectomy in the treatment of stage I non-small cell lung cancer. In: Pass HI (ed.). Lung Cancer: Principles and Practice. Philadelphia/Lippincott-Raven, Chap. 34, pg. 561-66, 1996.
28.
Read RC, Yoder G, Schaeffer RC. Survival after conservative resection for T1 N0 M0 non-small-cell lung cancer. Ann Thorac Surg. 1990;49:391–8. [PubMed: 2155592]
29.
Leonard JE, Wang QC, Kaplan N0. et al. Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates. Cancer Res. 1985;45:5263–9. [PubMed: 3876881]
30.
Bystryn JC, Bernstein P, Liu P. et al. Immunophenotype of human melanoma cells in different metastases. Cancer Res. 1985;45:5603–7. [PubMed: 2413993]
31.
Devessa SS, Blot WJ, Fraumeni JF Jr. Declining lung cancer rates among young men and women in the United States: a cohort analysis. J Natl Cancer Inst. 1989;81:1568–71. [PubMed: 2795682]
32.
Saccomanno G, Archer VE, Saunders RP. et al. Early indices of cancer risk among uranium miners with reference to modifying factors. Ann NY Acad Sci. 1976;271:377–83. [PubMed: 1069527]
33.
Pershagen G, Akerblom G, Axelson O. et al. Residential radon exposure and lung cancer in Sweden. N Engl J Med. 1994;330:159–64. [PubMed: 8264737]
34.
Ooi WL, Elston RC, Chen VW. et al. Increased familial risk for lung cancer. J Natl Cancer Inst. 1986;76:217–22. [PubMed: 3456060]
35.
Sellers TA, Bailey-Wilson JE, Elston RC. et al. Evidence for mendelian inheritance on the pathogenesis of lung cancer. J Natl Cancer Inst. 1990;82:1272–9. [PubMed: 2374177]
36.
Weinberg RA. Tumor suppressor genes. Science. 1991;254:1138–46. [PubMed: 1659741]
37.
Little CD, Nau MM, Carney DN. et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983;306:194–6. [PubMed: 6646201]
38.
Funa K, Steinholtz L, Nou E. et al. Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am J Clin Pathol. 1987;88:216–20. [PubMed: 3039835]
39.
Yokota J, Wada M, Yoshida T. et al. Heterogeneity of lung cancer cells with respect to the amplification and rearrangement of myc family oncogenes. Oncogene. 1988;2:607–11. [PubMed: 2838790]
40.
Aisner SC, Finkelstein DM, Ettinger DS. et al. The clinical significance of variant-morphology small-cell carcinoma of the lung. J Clin Oncol. 1990;8:402–8. [PubMed: 2155311]
41.
Rodenuhuis S, Slebos RJC, Evers SG, et al. The ras oncogene family and lung cancer. J Cell Biochem 1991;Supple 15F:3.
42.
Mukhopadhyay T, Tainsky M, Cavender AC. et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991;51:1744–8. [PubMed: 1998965]
43.
Georges RN, Mukhopadhyay T, Zhang Y. et al. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 1993;53:1743–6. [PubMed: 8467490]
44.
Schneider PM, Hung MC, Chiocca SM. et al. Differential expression of the c-erbB-2 gene in human small cell and non-small-cell lung cancer. Cancer Res. 1989;49:4968–71. [PubMed: 2569928]
45.
Weiner DB, Norderg J, Robinson R. et al. Expression of the neu gene-encoded protein (P185neu) in human non-small-cell carcinomas of the lung. Cancer Res. 1990;50:421–5. [PubMed: 1967224]
46.
Naylor SL, Johnson BE, Minna JD. et al. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 1987;329:451–4. [PubMed: 2821400]
47.
Horio Y, Takahashi T, Kuroishi T. et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small-cell lung cancer. Cancer Res. 1993;53:1–4. [PubMed: 8380124]
48.
Sozzi G, Tornielli S, Tagliabue E. et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 1997;57:5207–12. [PubMed: 9393735]
49.
Sozzi G, Pastorino U, Moiraghi L. et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032–7. [PubMed: 9823304]
50.
Sozzi G, Veronese ML, Negrini M. et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1997;85:17–26. [PubMed: 8620533]
51.
Ji L, Fang B, Yen N. et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 1999;59:3333–9. [PubMed: 10416589]
52.
Hollstein M, Sidransky D, Vogelstein B. et al. p53 mutations in human cancers. Science. 1991;253:49–53. [PubMed: 1905840]
53.
Suzuki H, Takahashi T, Kuroishi T. et al. p53 mutations of non-small-cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 1992;52:734–6. [PubMed: 1310070]
54.
Vahakangas KH, Samet JM, Metcalf RA. et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992;339:576–80. [PubMed: 1347094]
55.
Cajot JF, Anderson MJ, Lehman TA. et al. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cancer Res. 1992;52:6956–60. [PubMed: 1458487]
56.
Quinlan DC, Davidson AG, Summers CL. et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52:4828–31. [PubMed: 1324796]
57.
Mukhopadhyay T, Roth JA. A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res. 1993;53:4362–6. [PubMed: 8364931]
58.
Swisher SG, Roth JA, Nemunaitis J. et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:763–71. [PubMed: 10328106]
59.
Zhang WW, Fang X, Mazur W. et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5–13. [PubMed: 7621238]
60.
Fujiwara T, Grimm EA, Mukhopadhyay T. et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenoviral-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287–91. [PubMed: 8162565]
61.
Roth JA, Nguyen D, Lawrence DD. et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985–91. [PubMed: 8782455]
62.
Tomizawa Y, Sekido Y, Kondo M. et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A. 2001;98:13954–9. [PMC free article: PMC61148] [PubMed: 11717452]
63.
Zochbauer-Muller S, Fong KM, Virmani AK. et al. Aberrant promoter methylation of multiple genes in non-small-cell lung cancers. Cancer Res. 2001;61:249–55. [PubMed: 11196170]
64.
Ji L, Nishizaki M, Gao B. et al. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002;62:2715–20. [PMC free article: PMC3478680] [PubMed: 11980673]
65.
Wistuba II, Behrens C, Milchgrub S. et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 1999;18:643–50. [PubMed: 9989814]
66.
Mao L, Lee JS, Kurie JM. et al. Clonal genetic alterations in the lungs of current and former smokers [see comments] J Natl Cancer Inst. 1997;89:857–62. [PubMed: 9196251]
67.
Chung KY, Mukhopadhyay T, Kim J. et al. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res. 1993;53:1676–83. [PubMed: 8453641]
68.
Martini N, Bains MS, Burt ME. et al. Incidence of local recurrence in second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120–9. [PubMed: 7815787]
69.
Mathisen DJ, Jensik RJ, Feber LP. et al. Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg. 1984;88:502–10. [PubMed: 6482486]
70.
Thomas P, Rubinstein L. Lung Cancer Study Group. Cancer recurrence after resection: T1 N0 non-small-cell lung cancer. Ann.Thorac.Surg. 1990;49:242–7. [PubMed: 2154958]
71.
Thomas PA, Holmes EC, Piantadosi S. et al. Malignant disease appearing late after operation for T1 N0 non- small-cell lung cancer. J Thorac Cardiovasc Surg. 1993;106:1053–8. [PubMed: 8246538]
72.
Rosengart TK, Martini N, Ghosn P. et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 1991;52:773–9. [PubMed: 1929628]
73.
Bradley EC, Schecter GP, Matthews MJ. et al. Erythroeleukemia and other hemologic complications of intensive therapy in long-term survivors of small cell lung cancer. Cancer. 1982;49:221–3. [PubMed: 6274504]
74.
Boice JD Jr, Fraumeni JF Jr. Second cancer following cancer of the respiratory system in Connecticut, 1935-1982. NCI Monograms. 1985;68:83–98. [PubMed: 4088314]
75.
Christensen PH, Joergensen K, Munk J. et al. Hyperfrequency of pulmonary cancer in a population of 415 patients treated for laryngeal cancer. Laryngoscope. 1987;97:612–4. [PubMed: 3573910]
76.
de Vries N, Snow GB. Multiple primary tumors in laryngeal carcinoma. J Laryngol Othol. 1986;100:915–8. [PubMed: 3746107]
77.
World Health Organization. Histologic typing of lung tumors. In: World Health Organization, editors. International classification of tumors. Geneva: World Health Organization; 1991.
78.
Matthews MJ. World Health Organization: lung cancer classification. Chest. 1986;89:315S. [PubMed: 3514177]
79.
Weinstein IB, Arcoleo J, Lambert M. et al. Mechanisms of multistage chemical carcinogenesis and their relevance to respiratory tract cancer. Carcinogenesis. 1985;8:395–409. [PubMed: 3157453]
80.
Shimosato T, Kodama T, Kameya T. Morphogenesis of peripheral adenocarcinoma of the lung. In: Shimosato T, Melamed MR, Nettesheim P, editors. Morphogensis of lung cancer. Florida: CRCPress; 1982. p. 65–81.
81.
Valaitis J, Warren S, Gambel D. Increasing incidence of adenocarcinoma of the lung. Cancer. 1981;47:1042–7. [PubMed: 6261919]
82.
Vincent RG, Pickren JW, Lane WW. et al. The changing histopathology of lung cancer. a review of 16,082 cases. Cancer. 1977;39:1647–55. [PubMed: 192433]
83.
Wu AH, Henderson BE, Thomas DC. et al. Secular trends in histologic types of lung cancer. J Natl Cancer Inst. 1986;77:53–6. [PubMed: 3014199]
84.
Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev. 1991;1:29–34. [PubMed: 1845165]
85.
Mackay B, Lukeman JM, Ordonez NG. Anonymous tumours of the lung. In: MacKay B, Lukeman JM, Ordonez NG (eds.) Tumors of the Lung, Philadelphia/ WB Saunders, p. 285–322, 1991.
86.
Fargion S, Carney D, Mulshine J. et al. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986;46:2633–8. [PubMed: 3008997]
87.
Roggli VL, Vollmer RT, Greenberg SD. et al. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Human Pathol. 1985;16:569–79. [PubMed: 2987102]
88.
Chuang MT, Marchesky A, Tiestein AS. et al. Diagnosis of lung cancer by fiberoptic bronchoscopy: problems in the histologic classification of non-small-cell carcinoma. Thorax. 1984;39:175–8. [PMC free article: PMC459754] [PubMed: 6324409]
89.
Mooi WJ, Dingemans KP, Wagenar SS. et al. Ultrastructural heterogeneity of lung carcinomas: representativity of samples electron microscopy in tumor classification. Human Pathol. 1990;21:1227–34. [PubMed: 2249836]
90.
Churg A. The fine structure of large cell undifferentiated carcinoma of the lung. Evidence for its relation to squamous cell carcinomas and adenocarcinomas. Human Pathol. 1978;9:143–56. [PubMed: 640640]
91.
Auerbach O. Natural history of carcinoma of the lung. In: Fishman AP, editors. Pulmonary diseases and disorders. New York: McGraw-Hill; 1990:1388-96.
92.
Yesner R. Spectrum of lung cancer and ectopic hormones. Pathol Annu. 1978;1:217–40. [PubMed: 214740]
93.
Carter D, Marsh BR, Baker RR. et al. Relationships of morphology to clinical presentation in 10 cases of early squamous cell carcinoma of the lung. Cancer. 1976;37:1389–95. [PubMed: 1260659]
94.
Clayton F. Bronchoaleveolar carcinomas: cell types, patterns of growth, and prognostic collocates. Cancer. 1986;57:1555–60. [PubMed: 3004694]
95.
Manning JT Jr, Spujet GH, Tschen JA. Bronchoioalveolar carcinoma: the significance of two histopathologic types. Cancer. 1984;54:525–34. [PubMed: 6329505]
96.
Ginsberg SS, Buzaid AC, Stern H. et al. Giant cell carcinoma of the lung. Cancer. 1992;70:606–10. [PubMed: 1623475]
97.
Fishback NF, Travis WD, Moran CA. et al. Pleomorphic (spindle and giant cell) carcinomas of the lung: a clinopathologic study of 78 cases. Cancer. 1994;73:2936–45. [PubMed: 8199991]
98.
Travis WD, Linnoila RI, Tsokos MG. et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53. [PubMed: 1709558]
99.
Linnoila RI, Jensen SM, Steinberg SM. et al. Neuroendocrine differentiation in non-small-cell lung cancer correlates to favorable response to chemotherapy [abstract] Proc ASCO. 1989;8:248–9.
100.
Grazino SL, Mazid R, Newman N. et al. The use of neuroendocrine immunoparoxodize markers to predict chemotherapy response in patients with non-small-cell lung cancer. Clin Oncol. 1989;7:1398–406. [PubMed: 2550590]
101.
Gazdar AF, Kadoyama C, Venzon D, et al. Association between histologic type and neuroendocrine differentiation on drug sensitivity on lung cancer cell lines. Monograms NCI 1992;191-6. [PubMed: 1327032]
102.
Nauheim KS, Taylor JR, Skosey C. et al. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg. 1982;44:462–6. [PubMed: 3675050]
103.
Ishida T, Kaneko S, Yokoyma H. et al. Adenosquamous carcinoma of the lung. Clinical, pathologic and endohistochemical features. Am J Clin Pathol. 1992;97:678–85. [PubMed: 1575214]
104.
Takamori S, Noguchi M, Morinaga S. Clinical pathologic characteristics of adenosquamous carcinoma of the lung. Cancer. 1991;67:649–54. [PubMed: 1985759]
105.
Sridhar KS, Raub WA Jr, Duncan RC. The increasing recognition of adenosquamous lung carcinoma (1977-1986) Am J Clin Oncol. 1986;115:356–62. [PubMed: 1514535]
106.
Radke JR, Conway WA, Eyler WR. et al. Diagnostic accuracy in perpherial lung lesions: factors predicting success with flexible optic bronchoscopy. Chest. 1979;76:176–9. [PubMed: 456057]
107.
McCaughan BC, Martini N, Bains MS. Bronchial carcinoids: a review of 124 cases. J Thorac Cardiovasc Surg. 1985;89:8–17. [PubMed: 2981373]
108.
Paladugu RR, Benfield JR, Pak HY. et al. Bronchopulmonary kulchitzky cell carcinomas, a new classification scheme for typical and atypical carcinoids. Cancer. 1985;55:1303–11. [PubMed: 3971299]
109.
Merzak A, Raynal S, Rogers JP. et al. Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J Neurol Sci. 1994;127:125–33. [PubMed: 7707071]
110.
Martini N, Zaman MB, Bains MS. et al. Treatment and prognosis in bronchial carcinoids involving regional lymph nodes. J Thorac Cardiovasc Surg. 1994;107:1–6. [PubMed: 8283871]
111.
Vollmer RT, Ogen L, Crissman JD. Separation of small cell from non-small-cell lung cancer. Arch Pathol Lab Med. 1984;108:792–4. [PubMed: 6089696]
112.
Hirsch FR, Matthews MJ, Aisner S. et al. Histopathologic classification of small cell lung cancer. Changing comcepts and terminology. Cancer. 1988;62:973–77. [PubMed: 2842029]
113.
Mangun MD, Greco FA, Hainsworth JD Jr. et al. Combined small cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12. [PubMed: 2540288]
114.
Fraire AE, Johnson EH, Yesner R. et al. Prognostic significance of histopathologic subtype and stage in small cell lung cancer. Human Pathol. 1992;21:520–8. [PubMed: 1314777]
115.
Sehested M, Hirsch FR, Osterlind K. et al. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and post treatment specimens in 104 patients. Cancer. 1986;57:804–7. [PubMed: 3002587]
116.
Asamura H, Naruke T, Tsuchiya R. et al. What are the risk factors for arrhythmias after thoracic operations? A retrospective multivariate analysis of 267 consecutive thoracic operations. J Thorac Cardiovasc Surg. 1993;106:1104–10. [PubMed: 8246546]
117.
Gurney JW. Determining the likelihood of malignancy in solitary pulmonay nodules with Batesian analysis. Radiol. 1993;186:405–13. [PubMed: 8421744]
118.
Magilligan DJ Jr, Duvernoy C, Malik G. et al. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. Ann Thorac Surg. 1986;42:360–4. [PubMed: 3767508]
119.
Mondal A, Pradhan MC. Role of percutaneous fine needle aspiration cytology (FNAC) in detection of lung, pleural and mediatinal tumours-a study of 162 cases. Indian J Pathol Microbiol. 1991;34:253–8. [PubMed: 1818029]
120.
Mack MJ, Aronoff RJ, Acuff TE, et al. Present role of thoracoscopy in the diagnosis and treatment of diseases of the chest. Ann Thorac Surg 1992;54:403-8; discussion 407-9. [PubMed: 1510505]
121.
Johnson BE, Ihde DC, Makuch RW. et al. Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest. 1987;79:1629–34. [PMC free article: PMC424486] [PubMed: 3034978]
122.
Johnson BE, Battey J, Linnoila I. et al. Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. J Clin Invest. 1986;78:525–32. [PMC free article: PMC423589] [PubMed: 3016030]
123.
Kiefer PE, Bepler G, Kubasch M. et al. Amplification and expression of proto-oncogenes in human small cell lung cancer cell lines. Cancer Res. 1987;47:6236–42. [PubMed: 2824028]
124.
Nau MM, Brooks BJ, Battey J. et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985;318:69–73. [PubMed: 2997622]
125.
Ries LG, Pollack ES, Young JL. Cancer patient survival: surveillance, epidermiology, and end results program. J Natl Cancer Inst. 1983;70:693–709. [PubMed: 6572758]
126.
Berlin NI, Buncher CR, Fontana RS. The national cancer institute cooperative early launch cancer detection program. Results of the initial screen (prevalence): introduction. Am Rev Respir Dis. 1984;130:545–9. [PubMed: 6548343]
127.
Frost JK, Fontana RS, McClamed MR. et al. Early lung cancer detection: summary and conclusions. Am Rev Respir Dis. 1984;130:565–7. [PubMed: 6486554]
128.
Sanderson DR. Lung cancer screening—the Mayo study. Chest. 1986;89:S324.
129.
Tochman MS. Survival and mortality from lung cancer in a screened population: the Johns Hopkins study. Chest. 1986;89:325S–326S.
130.
Martini N. Results of the Memorial Sloan-Kettering study in screening for early lung cancer. Chest. 1986;89:S325.
131.
Miller AB. Update in epidemiology. Chest. 1986;89:S306–S307.
132.
Strauss GM. Measuring effectiveness of lung cancer screening: from consensus to controversy and back. Chest. 1997;112:216S–228S. [PubMed: 9337293]
133.
Patz EF, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343:1627–33. [PubMed: 11096172]
134.
Kubik A, Parkin DM, Khlat M. et al. Lack of benefit from semiannual screening for cancer of the lung—follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer. 1990;45:26–33. [PubMed: 2404878]
135.
Fontana RS, Sanderson DR, Woolner LB. et al. Screening for lung cancer. A critique of the Mayo lung project. Cancer. 1991;67:1155–64. [PubMed: 1991274]
136.
Black WC. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst. 2000;92:1280–2. [PubMed: 10944539]
137.
Kaneko M, Eguchi K, Ohmatsu H. et al. Peripheral lung cancer: Screening and detection with low-dose spiral CT versus radiography. Radiology. 1996;201:798–802. [PubMed: 8939234]
138.
Henschke CI, McCauley DI, Yankelevitz DF. et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99–105. [PubMed: 10408484]
139.
Swensen SJ, Jett JR, Sloan JA. et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002;165:508–13. [PubMed: 11850344]
140.
Cohen MH. Signs and symptoms of bronchogenic carcinoma. In: Straus MJ, editor. Lung cancer: clinical diagnosis and treatment. Philadelphia: Grune & Stratton; 1983. p. 97.
141.
Grippi MA. Clinical aspects of lung cancer. Sem Roentgenol. 1990;15:12–6. [PubMed: 2181676]
142.
Rodrigues N, Straus MJ. Superior vena caval syndrome. In: Straus MJ, editor. Lung cancer: clinical diagnosis and treatment. Philadelphia: Grune & Stratton; 1983. p. 323-7.
143.
Schraufnagel D, Hill R, Leech J. et al. Superior vena caval obstruction. Is it a medical emergency. Am J Med. 1981;70:1169–74. [PubMed: 7234887]
144.
Paulson D. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg. 1995;70:1095–103. [PubMed: 1186286]
145.
O'Connell RS, McLoud TC, Wilkins EW. Superior sulcus tumor: radiographic diagnosis and workup. Am J Roentgenol. 1983;140:25–9. [PubMed: 6600321]
146.
Johnson HJ, Fantone J, Flye MW. Histological evaluation of the nodules resected in the treatment of pulmonary metastatic disease. J Surg Oncol. 1982;21:1–4. [PubMed: 6955574]
147.
Light RW. Malignant pleural effusion. In: Pleural effusion. Philadelphia: Lea & Febiger; 1983. p. 77–89.
148.
Mountain CF. Prognostic implications of the international staging system for lung cancer. Semin Oncol. 1988;3:236–41. [PubMed: 3381104]
149.
Kondo H, Asamura H, Suemasu K. et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. J Thorac Cardiovasc Surg. 1993;106:1092–7. [PubMed: 8246544]
150.
Press OW, Livingston R. Management of malignant pericardial effusion and tamponade. JAMA. 1988;257:1088–93. [PubMed: 3806903]
151.
Matthews MJ. Problems in morphology and behavior of bronchopulmonary malignant disease. In: Israel L, Chahanian P, editor. Lung cancer: natural history, prognosis, and therapy. New York: Academic Press; 1976. p. 23.
152.
Chute CG, Greenberg ER, Baron J. et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer. 1985;56:2107–112. [PubMed: 2992757]
153.
Rosen ST, Aisner J, Makuch RW. et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Med. 1982;61:45–9. [PubMed: 6276648]
154.
Cohen M, Matthews MJ. A distinct clinicopathologic entity. Semin Oncol. 1978;5:234–7. [PubMed: 211637]
155.
Amatruda TT, Mulrow PJ, Gallagher JC. et al. Carcinoma of the lung with inappropriate antidiuresis. N Engl J Med. 1963;269:544–9. [PubMed: 14043255]
156.
Comis RL, Miller M, Ginsberg SJ. Abnormalities in water homeostasis in small cell anaplastic lung cancer. Cancer. 1983;51:161–8.
157.
Rassam JW, Anderson G. Incidence of paramalignant disorders in bronchogenic carcinoma. Thorax. 1975;30:86–90. [PMC free article: PMC470249] [PubMed: 164704]
158.
Greco FA, Hainsworth J, Sismani A, et al. Hormone production and paraneoplastic syndromes. In: Greco FA, Oldham RK, Bunn PA Jr, editors. Small cell lung cancer. New York: Grune & Stratton; 1981. p. 177–223.
159.
Bliss DP, Battey JF, Linnoila RI. et al. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst. 1990;82:305–8. [PubMed: 2153841]
160.
Broder LE, Primack A. Marker substance in bronchogenic carcinoma: a review. In: Straus MJ, editors.. Lung cancer: clinical diagnosis and treatment. New York: Grume & Stratton; 1983. p. 37–61.
161.
Yalow RS. Ectopic ACTH in carcinoma of the lung. In: Muggia FM, Rosencweig M, editors. Lung cancer progress in therapeutic research. New York: Raven Press; 1979. p. 209.
162.
Gilby ED, Rees LH, Bondy PK. Ectopic hormones as markers of response to therapy in cancer. J Exp Med. 1975;375:132.
163.
Shepherd FA, Laskey J, Evans WK. et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992;10:21–5. [PubMed: 1309381]
164.
Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Intern Med. 1974;80:205–8. [PubMed: 4359740]
165.
Budayr AA, Nissenson RA, Klein RF. et al. Increased serum levels of parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med. 1989;111:807–12. [PubMed: 2817628]
166.
Blackman MR, Weintraub BD, Rosen SW. et al. Human placental and pituitary glycoprotine hormones and their subunits as tumor markers: a quantitative assessment. J Natl Cancer Inst. 1980;65:81–93. [PubMed: 6248674]
167.
Gailani S, Chu TM, Nussbaum A. et al. Human chorionic gonadotrophins (HCG) in non-trophoblastic neoplasms. Assessment of abnormalities of HCG and CEA in bronchogenic and digestive neoplasms. Cancer. 1976;38:1684–92. [PubMed: 991086]
168.
Hattori M, Imura H, Matsukura S. et al. Multiple-hormone producing lung carcinoma. Cancer. 1979;43:2429–37. [PubMed: 222425]
169.
Johnson BE,Chute JP. Extrapulmonary syndromes associated with lung tumors. In: Fishman AP, Elias JA, Grippi MI, Kaiser LR, Senior RM (eds.) Pulmonary Diseases and Disorders, 3rd Ed., Vol. 2, Chap 116, pg. 1841-49, 1988.
170.
Patel AM, Davila DG, Peters SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc. 1993;68:278–81. [PubMed: 8474272]
171.
Lennon VA, Lambert EH. Autoantibodies bind solubilized calcium channel-w-conotoxin complexes with small cell lung carcinoma: a diagnostic aid for Lambert-Eaton myasthenic syndrome. Mayo Clin Proc. 1989;64:1498–501. [PubMed: 2557495]
172.
Lambert EH, Rooke ED, Eatton LM. Myasthenic syndrome occasionally associated with bronchial neoplasm. In: Viets HR, editor. Myasthenia gravis. Springfield: Charles C. Thomas; 1961. p. 362.
173.
O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain. 1988;111:577–82. [PubMed: 2838124]
174.
Eaton LM, Lambert EH. Electromyography and electrical stimulation of nerves in diseases of motor unit: observation on myasthenic syndrome associated with malignant tumors. JAMA. 1957;163:1117–24. [PubMed: 13405774]
175.
Lambert EH, Lennon VA. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve. 1988;11:1133–6. [PubMed: 3226429]
176.
McEvoy KM, Windebank AJ, Daube JR. et al. 3,4-diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321:1567–72. [PubMed: 2555713]
177.
Gamou S, Shimosato Y, Shimizu N. Regulation of the epidermal growth factor receptor gene expression in a morphological variant isolated from an epidermal growth factor receptor-deficient small cell lung carcinoma cell line. Cell Growth Differ. 1990;1:351–9. [PubMed: 1980602]
178.
Crossland KD, Lee VK, Chen W. et al. T-cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol. 1991;146:4414–20. [PubMed: 1674958]
179.
Lundh H, Nisson O, Rosen I. Current therapy of the Lambert-Eaton myasthenic syndrome. Prog Brain Res. 1990;84:163–166. [PubMed: 2267294]
180.
Jenkyn LR, Brooks PL, Forcier RJ. et al. Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer. 1980;46:1123–7. [PubMed: 6260327]
181.
Graus F, Elkon KB, Cordon-Cardo C. et al. Sensory neuropathy and small cell lung cancer. Am J Med. 1986;80:45–7. [PubMed: 2417479]
182.
Kimmel DW, O'Neill BP, Lennon VA. Subacute sensory neuronopathy associated with small cell lung carcinoma: diagnosis aided by authimmune serology. Mayo Clin Proc. 1988;63:29–30. [PubMed: 2826934]
183.
Anderson NE, Rosenblum MK, Graus FW. et al. Autoantibodies in paraneoplastic syndromes associated with small cell lung cancer. Neurologh. 1988;38:1391–4. [PubMed: 2842702]
184.
Dalmau JD, Furneaux HM, Gralla RJ. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer. A quantitative Western blot analysis. Ann Neurol. 1990;27:544–8. [PubMed: 2163235]
185.
Aftermatt HJ, Rodriguez M, Scheithauer BW. et al. Paraneoplastic anti-Purkinje and type I anti-neuronol nuclear autoantibodies bind selectively to central, peripheral, and autonomic nervous system cells. Lab Invest. 1991;65:412–4. [PubMed: 1921331]
186.
Brennan LV, Craddock PR. Limbic encephalopathy as a nonmetastatic complication of oat cell lung cancer. Its reversal after treatment of the primary lung lesion. Am J Med. 1983;75:518–21. [PubMed: 6311015]
187.
Newman NJ, Bell IR, McKee AC. Paraneoplastic limbic encephalitis: neuropsychiatric presentation. Biol Psychiatry. 1990;27:529–53. [PubMed: 2155672]
188.
Ojeda VJ. Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and literature review. Cancer. 1984;53:1115–9. [PubMed: 6362838]
189.
Schuffler MD, Baird HW, Fleming CR. et al. Intestinal pseudo-obstruction as the presenting manifestation of small-cell carcinoma of the lung: a paraneoplastic neuropathy of the gastrointesntinal tract. Ann Intern Med. 1983;98:129–34. [PubMed: 6297344]
190.
Lennon VA, Sas DF, Busk MF. et al. Enteric neuronal autoantibodies in pseudoobstruction with small cell lung carcinoma. Gastroenterology. 1991;100:137–42. [PubMed: 1845756]
191.
Ogilvie H. Large-intestine colic due to sympathetic deprivation: a new clinical syndrome. Br Med Bull. 1948;2:671–6.
192.
Sodhi N, Camilleri M, Camoriano JK. et al. Autonomic function and motility in intestinal pseudo obstruction caused by paraneoplastic syndrome. Dig Dis Sci. 1989;34:1937–42. [PubMed: 2557192]
193.
Grunwald GB, Kornguth SE, Towfghi J. et al. Autoimmune basis for visual paraneoplastic syndrome in patients with small cell lung carcinoma: retinal immune deposits and ablation of rational ganglion cells. Cancer. 1987;60:780–6. [PubMed: 3036336]
194.
Hansen-Flaschen J, Nordberg J. Clubbing and hypertrophic osteoarthropathy. Clin Chest Med. 1987;8:287–94. [PubMed: 3304817]
195.
Parkash UBS. Hypertrophic pulmonary osteoarthropathy and clubbing. In: Sackner MA, Wanner A, editors. Weekly update: pulmonary medicine. Princeton, NJ: Biomedia; 1978. p. 2.
196.
Dickinson CJ, Martin JF. Megakaryoctyes and platelet clumps as the cause of finger clubbing. Lancet. 1987;2:1434–40. [PubMed: 2891996]
197.
MacDonald RA, Robbins SL. The significance of nonbacterial thrombotic endocarditis: an autopsy and clinical study of 78 cases. Ann Intern Med. 1957;46:255–9. [PubMed: 13403513]
198.
Anderson HA, Prakash UBS. Diagnosis of symptomatic lung cancer. Semin Respir Med. 1982;3:165–9.
199.
Silvis SE, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA. 1970;211:1852–6. [PubMed: 5467116]
200.
Brugarolas A, Mink IB, Elias EG. et al. Correlation of hyperfibrinogenemia with major thromboembolism in patients with cancer. Surg Gynecol Obset. 1973;136:75–9. [PubMed: 4682267]
201.
Coon WW. Risk factors in pulmonary embolism. Surg Gynecol Obstet. 1976;143:385–8. [PubMed: 959958]
202.
Gore JM, Appelbaum JS, Greene HL. et al. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med. 1982;96:556–60. [PubMed: 7073147]
203.
Belt RJ, Leite C, Haas CD. et al. Incidence of hemorrhagic complications in patients with cancer. JAMA. 1978;239:2571–7. [PubMed: 660790]
204.
Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trouseu's syndrome revisited. Blood. 1983;62:14–9. [PubMed: 6407544]
205.
Krauth D, Holden A, Knapic N. et al. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer. 1987;59:983–5. [PubMed: 3815277]
206.
Schafer AI. The hypercoagulable states. Ann Intern Med. 1985;102:814–8. [PubMed: 3158262]
207.
Mintz U, DeMeester TR, Golomb HM. et al. Subsequential staging in bronchogenic carcinoma. Chest. 1979;76:653–7. [PubMed: 228910]
208.
Paulson DL, Reisch JS. Long-term survival after resection for bronchogenic carcinoma. Ann Surg. 1976;184:324–30. [PMC free article: PMC1344391] [PubMed: 962400]
209.
Van Raemdonck DE, Schneider A, Ginsberg RJ. Surgical treatment for higher stage non-small cell lung cancer. Ann Thorac Surg. 1992;54:999–1013. [PubMed: 1329685]
210.
Jaklitsch MT, Strauss GM, Sugarbaker DJ. Neoadjuvant and adjuvant therapy in the management of locally advanced non-small cell lung cancer. World J Surg. 1993;17:729–34. [PubMed: 8109109]
211.
Holmes EC. Adjuvant treatment in resected lung cancer. Semin Surg Oncol. 1990;6:263–7. [PubMed: 2237084]
212.
Yano T, Hara N, Ichinose Y. et al. Results of pulmonary resection of metastatic colorectal cancer and its application. J Thorac Cardiovasc Surg. 1993;106:876–9. [PubMed: 8231210]
213.
Glazer GM, Francis IR, Shirazi KK. et al. Evaluation of the pulmonary hilum: comparison of conventional radiography, 55 degree posterior oblique tomography, and dynamic computed tomography. J Comput Assist Tomogr. 1983;7:983–9. [PubMed: 6313775]
214.
Seely JM, Mayo JR, Miller RR, et al. T1 Lung Cancer—prevalence of mediastinal nodal metastases and diagnostic accuracy of CT radiology 1993;186:129-32. [PubMed: 8416552]
215.
McKenna RJ, Libshitz HI, Mountain CE. et al. Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer. Chest. 1985;88:206–10. [PubMed: 4017674]
216.
Nesbitt JC, Moores DW. Staging of lung cancer. In: Roth JA, Ruchdeschel JC, Weisenburg TH, editors. Thoracic oncology. Philadelphia: WB Saunders; 1995. p. 84–103.
217.
Rea HH, Shevland JE, House AJ. Accuracy of computed tomographic scanning in the assessment of the mediastinum in bronchial carcinoma. J Thorac Cardiovasc Surg. 1981;81:825–9. [PubMed: 7230853]
218.
Libshitz HI, McKenna RJ Jr, Mountain CF. Patterns of mediastinal metastases in bronchogenic carcinoma. Chest. 1986;90:229–32. [PubMed: 3015502]
219.
Daly BDT, Faling LJ, Pugatch RD. et al. Computer tomography: an effective technique for mediastinal staging in lung cancer. J Thorac Cardiovasc Surg. 1984;88:486–94. [PubMed: 6482485]
220.
Richey HM, Matthews JI, Helsel RA. et al. Thoracic CT scanning in the staging of bronchogenic carcinoma. Chest. 1984;85:218–21. [PubMed: 6319088]
221.
Daly BDT. N2 lung cancer: outcome in patients with false-negative computed tomographic scans of the chest. J Thorac Cardiovasc Surg. 1993;105:904–11. [PubMed: 8487569]
222.
Bekerman C, Caride VJ, Hoffer PB. et al. Noninvasive staging of lung cancer: indications and limitations of gallium-67 citrate imaging. Radiol Clin North Am. 1990;28:497–501. [PubMed: 2183260]
223.
Ak I, Stokkel MPM, Pauwels EKJ. Positron emission tomography with 2-[F-18]fluoro-2-deoxy-d-glucose in oncology Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol. 2000;126:560–74. [PubMed: 11043393]
224.
Fischer BMB, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and stagine of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659–66. [PubMed: 11902536]
225.
Marom EM, Erasmus JJ, Patz EF. Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer. 2000;28:187–202. [PubMed: 10812188]
226.
Poncelet AJ, Lonneux M, Coche E. et al. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardio-Thoracic Surg. 2001;20:468–74. [PubMed: 11509265]
227.
Ryu JS, Choi NC, Fischman AJ. et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87. [PubMed: 11804691]
228.
Richardson RH, Zavela DC, Jukerjee PK. et al. The use of fiberoptic bronchoscopic and brush biopsy in the diagnosis of suspected pulmonary malignancy. Am Rev Respir Dis. 1974;109:63–6. [PubMed: 4809165]
229.
Shure D. Fiberoptic bronchoscopy: diagnostic applications. Clin Chest Med. 1987;8:1–13. [PubMed: 3568586]
230.
Pirozynski M. Bronchoalveolar lavage in the diagnosis of peripheral, primary lung cancer. Chest. 1992;102:372–4. [PubMed: 1643916]
231.
Zarbo RJ, Fenoglio-Preiser CM. Interinstitutional database for comparison of performance in lung fine-needle aspiration cytology. Arch Pathol Lab Med. 1992;116:463–70. [PubMed: 1580748]
232.
Sinner WN. Pulmonary neoplasmas diagnosed with transthoracic needle biopsy. Cancer. 1979;43:1533–40. [PubMed: 445349]
233.
Sagel SS, Ferguson TB, Forrest JV. et al. Percutaneous transthoracic aspiration needle biopsy. Ann Thorac Surg. 1978;26:399–405. [PubMed: 753154]
234.
Calhoun P, Feldman PS, Armstrong P. et al. The clinical outcome of needle aspirations of the lung when cancer is not diagnosed. Ann Thorac Surg. 1986;41:592–6. [PubMed: 3718033]
235.
Sinner WN, Sagel SS, Fry WA. Needle biopsy for the diagnosis of intrathoracic lesions: Transthoracic needle biopsy. In: Kittle FC, editor. Current controversies in thoracic surgery. Philadelphia: WB Saunders; 1986. p. 87–91.
236.
Schieppati E. Mediastinal lymph node puncture through the tracheal carina. Surg Gynecol Obstet. 1958;110:243–6. [PubMed: 13580767]
237.
Wang KP, Terry PB. Transbronchial needle aspiration in the diagnosis and staging of bronchogenic carcinoma. Ann Rev Respir Dis. 1983;127:344–7. [PubMed: 6830056]
238.
Bhat N, Bhagat P, Pearlman ES. et al. Transbronchial needle aspiration biopsy in the diagnosis of pulmonary neoplasms. Diag Cytopathol. 1990;6:14–7. [PubMed: 2323291]
239.
Salath'e M, Sol'er M, Bolliger CT. et al. Transbronchial needle aspiration in routine fiberoptic bronchoscopy. Resp. 1992;59:5–8. [PubMed: 1579719]
240.
Harrow E, Halber M, Hardy S. et al. Bronchochoscopic and roentenographic correlates of a positive transbronchial needle aspiration in the staging of lung cancer. Chest. 1991;100:1592–6. [PubMed: 1959401]
241.
Schenk DA, Chambers SL, Derdak S. et al. Comparison of the Wang 19-gauge and 22-gauge needles in the mediastinal staging of lung cancer. Am Rev Respir Dis. 1993;147:1251–8. [PubMed: 8484639]
242.
Wang KP, Britt EJ. Needle brush in the diagnosis of lung mass or nodule through flexible bronchoscopy. Chest. 1991;100:1148–50. [PubMed: 1914576]
243.
Skinner DB. Scalene lymph node biopsy. N Engl J Med. 1963;268:1324–7. [PubMed: 13977903]
244.
Schatzlein MH, McAuliffe S, Orringer MB. et al. Scalene node biopsy in pulmonary carcinoma: when is it indicated? Ann Thorac Surg. 1981;31:322–4. [PubMed: 7212833]
245.
Bernstein MP, Ferrara JJ, Brown L. Effectiveness of scalene node biopsy for staging of lung cancer in the absence of palpable adenopathy. J Surg Oncol. 1985;29:46–8. [PubMed: 3990311]
246.
Yee J, Llewellyn GA, Williams PA. et al. Scalene lymph node dissection: a study of 354 consecutive dissections. Am J Surg. 1969;118:596–8. [PubMed: 5821701]
247.
Dartevelle PG, Khaliefe J, Chapellier A. et al. Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases. Ann Thorac Surg. 1988;46:68–72. [PubMed: 3382290]
248.
Wang K, Haponik EF, Guputa PK. et al. Flexible transbronchial needle aspiration: technical considerations. Ann Otol Rhinol Laryngol. 1985;93:233–6. [PubMed: 6732109]
249.
Schenk DA, Bower JH, Bryan CL. et al. Transbronchial needle aspirations staging of bronchogenic carcinoma. Am Rev Respir Dis. 1986;134:146–8. [PubMed: 3014934]
250.
Harken DE, Black H, Clauss R. et al. A simple cervico-mediastinal exploration for tissue diagnosis of intrathoracic disease. With comments on the recognition of inoperable carcinoma of the lung. N Engl J Med. 1954;251:1041–5. [PubMed: 13214387]
251.
Carlens E. Mediastinoscopy: a method for inspection and tissue biopsy in the superior mediastinum. Chest. 1959;36:343–8. [PubMed: 13807712]
252.
Luke WP, Pearson FG, Todd TRJ. et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986;91:53–6. [PubMed: 3941559]
253.
Coughlin M, Deslauriers J, Beaulieu M. et al. Role of mediastinoscopy in pretreatment staging of patients with primary lung cancer. Ann Thorac Surg. 1985;40:556–60. [PubMed: 4074003]
254.
Inculet, R, Lefcoe, M, Winton, T, et al. The effectiveness of mediastinoscopy in the nodal staging of lung cancer. Proc Soc Thorac Surg 31st 1995;Abstract 50;138–139.
255.
Lopez L, Varela A, Freixinet J. et al. Extended cervical mediastinoscopy: prospective study of 50 patients. Ann Thorac Surg. 1994;57:555–8. [PubMed: 8147621]
256.
Bergh NP, Larsson S. The significance of various types of mediastinal lymph node metastases in lung cancer. In: Jepssen O, Ruhbek-Sorenson H, editors. Mediastinoscopy: proceedings of an international symposium. Odense, Denmark: Odense University Press; 1971. p. 36-9.
257.
Ginsberg RJ. Evaluaion of the mediastinum by invasive techniques. Surg Clin North Am. 1987;67:1025–7. [PubMed: 3629422]
258.
Ginsberg RJ, Rice TW, Goldberg M. et al. Extended cervical mediastinoscopy: a single stage procedure for bronchogenic carcinoma of the left upper lobe. J Thorac Cardiovasc Surg. 1987;94:673–7. [PubMed: 3669695]
259.
McNeill TM, Chamberlain JM. Diagnostic anterior mediastinotomy. Ann Thorac Surg. 1966;2:532–5. [PubMed: 5934068]
260.
Jacobaeus HC. Uber die moglichkeit, die xystoskopie bei untersuchung seroser hohlungen anzuwenden. Munch Med Wsch. 1910;57:2090–2.
261.
Landreneau RJ, Hazelrigg SR, Mack MJ. et al. Thoracoscopic mediastinal lymph node sampling: useful for mediastinal lymph node stations inaccessible by cervical mediastinoscopy. J Thorac Cardiovasc Surg. 1993;106:554–8. [PubMed: 8361201]
262.
Coia LR, Sauter ER. Esophageal cancer. [Review]. Curr. Probl. Cancer. 1994;18:189–247. [PubMed: 7533069]
263.
Rice TW. Thoracoscopy in the staging of thoracic malignancies. In: Kaiser LR, Daniel TM, editors. Thoracoscopic surgery. Boston: Little Brown Company; 1993. p. 153–162.
264.
Landreneau RJ, Mack MJ, Hazelrigg SR. et al. Video-assisted thoracic surgery: basic technical concepts and intercostal approach strategies. Ann Thorac Surg. 1992;54:800–7. [PubMed: 1417251]
265.
Roviaro GC, Varoli F, Rebuffat C, et al. Video thoracoscopic approach for lung cancer. In: Motta G, editor. Staging and treatment. Lung cancer frontiers in science and treatment. Geneoa, Italy: Grafica, LP; 1994. p. 325-8.
266.
Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 1978;76:832–6. [PubMed: 713589]
267.
Tisi GM, Friedman PJ, Peters RM. et al. American Thoracic Society: clinical staging of primary lung cancer. Am Rev Respir Dis. 1983;127:659–61. [PubMed: 6846945]
268.
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging [see comments] Chest. 1997;111:1718–23. [PubMed: 9187199]
269.
Denoix PF. Enquete permanent dans les centres anticancereaux. Bull Inst Nat Hyg. 1946;1:70–5.
270.
Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225S–233S. [PubMed: 3514171]
271.
Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7. [PubMed: 9187198]
272.
Mountain CF. Clinical biology of small cell carcinoma: relationship to surgical therapy. Sem Oncol. 1978;5:272–9. [PubMed: 211638]
273.
Meyer JA. Effect of histologically verified TNM stage on disease control in treating small cell carcinoma of the lung. Cancer. 1985;55:1747–52. [PubMed: 2983862]
274.
Roswit B, Patno ME, Rapp R. et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiol. 1968;90:688–92. [PubMed: 4170866]
275.
Idhe DC, Makuch RW, Carney DN. et al. Prognostic implications of sites of metastases with patients with small cell carcinoma of the lung given intensive combination chemotherapy. Am Rev Respir Dis. 1981;123:500–7. [PubMed: 6263137]
276.
Ihde DC, Sims EG, Matthews MJ. et al. Bone marrow metastases in small cell carcinoma of the lung: frequency, description, and influence on chemotherapeutic toxicity and prognosis. Blood. 1979;53:667–86. [PubMed: 218597]
277.
Kelly BW, Morris JF, Harwood BP. et al. Methods and prognostic value of bone marrow examination in small cell carcinoma of the lung. Cancer. 1984;53:99–102. [PubMed: 6317161]
278.
Lawrence JP, Eleff M, Behm FG. et al. Bone marrow examination in small cell carcinoma of the lung: comparison of Trephine biopsy with aspiration. Cancer. 1984;53:2188–93. [PubMed: 6322959]
279.
Hansen HH, Dombernosky P, Hirsch RF. Staging procedures and prognostic features in small cell antiplastic bronchogenic carcinoma. Sem Oncol. 1978;5:280–7. [PubMed: 211639]
280.
Campling B, Quirt I, DeBoer G. et al. Is bone marrow examination in small cell lung cancer really necessary? Ann Intern Med. 1986;105:508–12. [PubMed: 3019199]
281.
Carney DN, Redmond O, Harford P. et al. Bone marrow involvement by small cell lung cancer using magnetic residence imaging [abstract] Proc ASCO. 1989;8:228–9.
282.
Hirsch RR, Hansen HH, Hainau B. Bilateral bone-marrow examinations in small cell anaplastic carcinoma of the lung. Acta Pathol Microbiol Scand. 1979;87:59–62. [PubMed: 217234]
283.
Sculier JP, Feld R, Evans WK. et al. Neurologic disorders in patients with small cell lung cancer. Cancer. 1987;60:2275–83. [PubMed: 2830955]
284.
McCormack PM, Attiyeh FF. Resection of pulmonary metastases from colorectal cancer. Am Soc Colon Rect Surg. 1979;22:553–6. [PubMed: 527448]
285.
Burgess RE, Burgess VF, Dibella NJ. Brain metastases in small cell carcinoma of the lung. JAMA. 1979;242:2084–6. [PubMed: 226730]
286.
Nugent JL, Bunn PA, Matthews MJ. et al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival. Cancer. 1979;44:1885–93. [PubMed: 227582]
287.
Levintan N, Hong WK, Byrne RE. et al. The role of computerized cranial tomography in the staging of small cell carcinoma of the lung. Cancer. 1984;68:1375–80. [PubMed: 6094002]
288.
Johnson DH, Windham WW, Allen JH. et al. Limited value of CT brain scans in the staging of small cell lung cancer. Am J Neuroradiol. 1982;3:649–53. [PubMed: 6295121]
289.
Poon PY, Feld R, Evans WK. Computed tomography of the brain, liver, and upper adbomen in the staging of small cell carcinoma of the lung. J Comput Assis Tomogr. 1982;6:963–8. [PubMed: 6292272]
290.
Mulshine J, Makuch RW, Johnson-Early A. et al. Diagnosis and significance of liver metastases in small cell carcinoma of the lung. Clin Oncol. 1984;2:733–41. [PubMed: 6330314]
291.
Dombernowsky P, Hirsch F, Hansen HH. et al. Peritoneoscopy in the staging of 190 patients with small-cell anaplastic carcinoma of the lung with special reference to subtyping. Cancer. 1978;41:2008–12. [PubMed: 206345]
292.
Dunnick NR, Ihde DC, Johnston-Early A. Abdominal CT in the evaluation of small cell carcinoma of the lung. Am J Radiol. 1979;133:1085–8. [PubMed: 228542]
293.
Sculier JP, Feld R, Evans WK. et al. Carcinoembryonic antigen: a useful prognostic marker in small cell lung cancer. J Clin Oncol. 1985;3:1349–54. [PubMed: 2995598]
294.
Feld R, DeBoer G, Sagman U. Prognostic factors for small cell-carcinoma of the lung. Eur J Cancer Clinical Oncol. 1988;24:353–5. [PubMed: 2838286]
295.
Goslin RH, Skarin AT, Zamcheck N. Carcinoembryonic antigen: a useful monitor of therapy of small cell lung cancer. JAMA. 1981;246:2173–6. [PubMed: 6270390]
296.
Idhe DC. Staging evaluation and prognostic factors in small cell lung cancer. In: Aisner J, editor. Lung cancer. New York: Churchill Livingstone; 1985. p. 241-6.
297.
Osterlind K, Idhe DC, Ettinger DS. et al. Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep. 1983;67:3–9. [PubMed: 6311412]
298.
Dearing MP, Steinberg SM, Phelps R. et al. Women small cell cancer patients live longer than men [abstract] Proc ASCO. 1988;7:199–200.
299.
Johnson BE, Steinberg SM, Phelps R. et al. Female patients with small cell lung cancer live longer than male patients. Am J Med. 1988;85:194–203. [PubMed: 2840825]
300.
Osterlind K, Hansen HH, Hansen M. et al. Long-term disease-free survival in small cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol. 1986;4:1307–12. [PubMed: 3018182]
301.
Poplin E, Thomson B, Whitacre M. et al. Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat Rep. 1987;71:291–6. [PubMed: 3028620]
302.
Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32. [PubMed: 6930515]
303.
Ginsberg MS, Arasmus J, Patz ER, et al. Imaging of the lung. In: Pearson FG, Cooper JD, Deslauriers RJ, Hiebert CA, Patterson GA, Urshel JC (eds.). Thoracic Surgery. 2nd edition, New York/Churchill-Livingstone, Chap. 21, p. 443-48, 2002.
304.
Salvarierra A, Baamonde C, Llamas JM. et al. Extrathoracic staging in bronchogenic carcinoma. Chest. 1990;97:1052–8. [PubMed: 2184992]
305.
Pagani JJ. Non-small cell lung carcinoma adrenal metastasis. Computed tomography and percutaneous neobiology in their diagnosis. Cancer. 1984;53:1058–62. [PubMed: 6692299]
306.
Newman SJ, Hansen HH. Frequency, diagnosis and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer. 1974;33:492–6. [PubMed: 4812766]
307.
Jacobs L, Kindel WR, Vincent RG. “Silent” brain metastasis from lung carcinoma determined by computerized tomography. Arch Neurol. 1977;34:650–93.
308.
Naruke T, Goya T, Tsuchiya R. et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440–7. [PubMed: 2842549]
309.
Hansen HH. Advanced non-small cell lung cancer: to treat or not to treat? J Clin Oncol. 1987;5:1711–7. [PubMed: 2824704]
310.
Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 1992;101:1013–8. [PubMed: 1313349]
311.
Martini N, McCaughan BC, McCormack PM, et al. The extent of resection for localized lung cancer: lobectomy. In: Kittle CF, editor. Current controversies in thoracic surgery. Philadelphia: WB Saunders; 1986. p. 171-4.
312.
Prestidge BR, Cox RS, Johnson DW. Non-small cell lung cancer: treatment results at a USAF referral center. Mil Med. 1991;156:479–83. [PubMed: 1660112]
313.
Daly RC, Trastek VF, Pairolero PC. Bronchoalveolar carcinoma: factors affecting survival. Ann Thorac Surg. 1991;51:368–76. [PubMed: 1998413]
314.
Thomas PA, Piantadose S. Lung Cancer Study Group. Postoperative T1 N0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 1978;94:349–54.
315.
Holmes EC. Treatment of stage II lung cancer (T1N1 and T2N1) Surg Clin North Am. 1987;67:945–58. [PubMed: 3629430]
316.
Ludwig Lung Cancer Study Group. Patterns of failure in patients with resected stage I and II non-small cell carcinoma of the lung. Ann Surg. 1987;205:67–71. [PMC free article: PMC1492883] [PubMed: 3026260]
317.
Martini N, Burt ME, Bains MS. et al. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg. 1992;54:460–6. [PubMed: 1324654]
318.
Fowler WC, Langer CJ, Curran WJ Jr. et al. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg. 1993;55:986–9. [PubMed: 8385447]
319.
McCaughan BC, Martini N, Bains MS. et al. Chest wall invasion in carcinoma of the lung. J Thorac Cardiovasc Surg. 1985;89:836–41. [PubMed: 2987619]
320.
Van de Wal HJCM, Lacquet LK, Jongerius CM. En bloc resection for bronchogenic carcinoma with chest wall invasion. Acta Chir Belg. 1985;85:89–93. [PubMed: 4013585]
321.
Ratto GB, Piacenza G, Frola C. et al. Chest wall involvement by lung cancer: computed tomographic detection and results of operation. Ann Thorac Surg. 1991;51:182–7. [PubMed: 1846522]
322.
Albertucci M, DeMeester TR, Rothberg M. et al. Surgery and the management of peripheral lung tumors adherent to the parietal pleura. J Thorac Cardiovasc Surg. 1992;103:8–14. [PubMed: 1309467]
323.
Mountain CF. The biological operability of stage III non-small cell lung cancer. Ann Thorac Surg. 1985;40:601–7. [PubMed: 4015245]
324.
Watanabe Y, Shimizu N, Oda M. et al. Results in 104 patients undergoing bronchoplastic procedures for bronchial lesions. Ann Thorac Surg. 1990;50:607–11. [PubMed: 2222051]
325.
Allen MS, Mathisen DJ, Grillo HC. et al. Bronchogenic carcinoma with chest wall invasion. Ann Thorac Surg. 1991;51:948–51. [PubMed: 2039324]
326.
Nakahashi H, Yasumoto K, Ishida T. et al. Results of surgical treatment of patients with T3 non-small cell lung cancer. Ann Thorac Surg. 1988;46:178–85. [PubMed: 2840868]
327.
Watanabe Y, Hayashi Y, Shimizu J. et al. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422–6. [PubMed: 1650679]
328.
Naruke T, Goya T, Tsuchiya R. et al. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg. 1988;46:603–10. [PubMed: 2848463]
329.
Burt ME, Pomerantz AH, Bains MS. et al. Results of surgical treatment of stage III lung cancer invading the mediastinum. Surg Clin North Am. 1987;67:987–1000. [PubMed: 2820072]
330.
Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987;67:1037–49. [PubMed: 3629423]
331.
Pearson FG, Delarue NC, Ilves R. et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg. 1982;83:1–11. [PubMed: 7054602]
332.
Watanabe Y, Shimizu J, Oda M. et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg. 1991;51:253–61. [PubMed: 1846524]
333.
Regnard JF, Magdeleinat P, Azoulay D. et al. Results of resection for bronchogenic carcinoma with mediastinal lymph node metastases in selected patients. Eur J Cardiothorac Surg. 1991;5:583–9. [PubMed: 1772669]
334.
Kirsh MM, Sloan H. Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location. Ann Thorac Surg. 1982;33:459–62. [PubMed: 7082083]
335.
Ihde DC, Minna JD. Non-small cell lung cancer. Part one: biology, diagnosis, and staging. Curr Probl Cancer. 1991;15:63–9. [PubMed: 1649734]
336.
Mathisen DJ, Grillo HC. Carinal resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1991;102:16–22. [PubMed: 2072721]
337.
Tsuchiya R, Goya T, Naruke T. et al. Resection of tracheal carina for lung cancer. J Thorac Cardiovasc Surg. 1990;99:779–87. [PubMed: 2329816]
338.
Dartevelle P, Marzelle J, Chapelier A. et al. Extended operations for T3–T4 primary lung cancers. Indications and results. Chest. 1989;96:51S–55S. [PubMed: 2737003]
339.
Macchiarini P, Buonaguidi R, Hardin M. et al. Results and prognostic factors of surgery in the management of non-small cell lung cancer with solitary brain metastases. Cancer. 1991;68:300–4. [PubMed: 1648994]
340.
Tsuchiya R, Asamura H, Kondo H. et al. Extended resection of the left atrium, great vessesl, or both for lung cancer. Ann Thorac Surg. 1994;57:960–5. [PubMed: 8166550]
341.
Magilligan DJ. Treatment of lung cancer metastatic to the brain. Surg Clin North Am. 1987;67:1073–8. [PubMed: 3629424]
342.
Burt M, Wronski M, Arbit E. et al. Resection of brain metastases from non-small-cell lung carcinoma. results of therapy. J Thorac Cardiovasc Surg. 1992;103:399–411. [PubMed: 1312184]
343.
Davies HM. Recent advances in the surgery of the lung and pleura. Br J Surg. 1914;1:228–31.
344.
Brunn HB. Surgical principles underlying one-stage lobectomy. Arch Surg. 1929;18:490–6.
345.
Graham EA, Singer JJ. Successful removal of the entire lung for carcinoma of the bronchus. JAMA. 1933;101:1371–4. [PubMed: 4210873]
346.
Rusch VW, Albain KS, Crowley JJ. et al. Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Ann Thorac Surg. 1994;58:290–5. [PubMed: 8067822]
347.
Albain K, Rusch V, Crowley J. et al. Concurrent cisplatin/etoposide plus chest radiation followed by surgery for stages IIIA (N2) and IIIB nonsmall cell lung cancer. Proc Am Soc Clin Oncol. 1994;13:337–42. [PubMed: 7636530]
348.
Albain KS, Crowley JJ, LeBlanc M. et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618–26. [PubMed: 1651993]
349.
Finkelstein DM, Ettingter DS, Ruckdeschel JC. Long-term survivors in metastatic non small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1986;4:702–9. [PubMed: 3701389]
350.
Au J, el-Oakley R, Cameron EW. Pneumonectomy for bronchogenic carcinoma in the elderly. Eur J Cardiothorac Surg. 1994;8:247–50. [PubMed: 8043286]
351.
Miller JI Jr. Thallium imaging in preoperative evaluation of the pulmonary resection candidate. Ann Thorac Surg. 1992;54:249–52. [PubMed: 1637213]
352.
Lette J, Waters D, Lassonde J. et al. Postoperative myocardial infarction and cardiac death. Ann Surg. 1990;211:84–90. [PMC free article: PMC1357899] [PubMed: 2294849]
353.
Miller DL, Orszulak TA, Pairolero PC. et al. Combined operation for lung cancer and cardiac disease. Ann Thorac Surg. 1994;58:989–94. [PubMed: 7944820]
354.
Yokoyama T, Derrick MJ, Lee AW. Cardiac operation with associated pulmonary resection. J Thorac Cardiovasc Surg. 1993;105:912–7. [PubMed: 8387618]
355.
Steen PA, Tinker JH, Tarhan S. Myocardial infarction after anesthesia and surgery. JAMA. 1978;239:2566–70. [PubMed: 660789]
356.
Wells PH, Kaplan JA. Optimal management of patients with ischemic heart disease for noncardiac surgery by complementary anesthesiologist and cardiologist interaction. Am Heart J. 1981;102:1029–37. [PubMed: 7032265]
357.
Mathisen DJ, Wain JC. Cardiac complications following pulmonary resection. Chest Surg Clin N Am. 1992;2:793–802.
358.
Bechard D, Wetstein L. Assessment of exercise oxygen consumption as preoperative criterion for lung resection. Ann Thorac Surg. 1987;44:344–9. [PubMed: 3662680]
359.
Olsen GN, Weinman DS, Boltman JWR. et al. Submaximal invasive exercise testing and quantitative lung scanning in the evaluation for tolerance of lung resection. Chest. 1989;95:267–73. [PubMed: 2914473]
360.
Morice RC, Peters EJ, Rayn MB. et al. Exercise testing in the evaluation of patients at high risk for complications from lung resection. Chest. 1992;101:356–63. [PubMed: 1735254]
361.
Ferguson MK, Reeder LB, Mick M. Optimizing selection of patients for major lung resection. Ann Thorac Surg. 1995;109:275–83. [PubMed: 7853881]
362.
Brundler H, Chen S, Perruchoud AP. Right heart catherterization in the pre-operative evaluation of patients with lung cancer. Resp. 1985;48:261–8. [PubMed: 4070803]
363.
Grossman W, Braunwald E. Pulmonary hypertension. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Saunders; 1992. p. 790.
364.
Fee HJ, Holmes EC, Gerwitz HS, et al. Role of pulmonary vascular resistance measurements in preoperative evaluation of candidates for pulmonary resection. 1989. [PubMed: 642548]
365.
Lewis JW Jr, Basanfar M, Gabriel F. et al. Right heart function and prediction of respiratory morbidity in patients undergoing pneumonectomy with moderately severe cardiopulmonary dysfunction. J Thorac Cardiovasc Surg. 1994;108:169–75. [PubMed: 8028362]
366.
Maassen W. The stagine issue-problems: accuracy of mediastinoscopy. In: Delarue NC, Escapasse H, editors. International trends in general thoracic surgery. Philadelphia: WB Saunders; 1985. p. 42–53.
367.
Ginsberg RJ, Hill LD, Eagan RT. et al. Modern thirty-day operative mortality for surgical resections in lung cancer. J Thorac Cardiovasc Surg. 1983;86:654–8. [PubMed: 6632940]
368.
Harpole DH, DeCamp MM, Daley J. et al. Prognostic models of 30-day morbidity and mortality after major pulmonary resection. J Thorac Cardiovasc Surg. 1999;117:969–79. [PubMed: 10220692]
369.
Putnam JB Jr, Lammermeier DE, Colon R. et al. Predicted pulmonary function and survival after pneumonectomy for primary lung carcinoma. Ann Thorac Surg. 1990;49:909–15. [PubMed: 2369189]
370.
Walsh GL, O'Connor M, Willis KM. et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg. 1995;60:1563–70. [PubMed: 8787445]
371.
Johnston WW. Cytologic diagnosis of lung cancer: Principles and problems. Pathol Res Pract. 1986;181:1–35. [PubMed: 2422636]
372.
Vaporciyan AA, Merriman KW, Ece F. et al. Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation. Ann Thorac Surg. 2002;73:420–5. [PubMed: 11845853]
373.
Goldstraw P. Treatment of postpneumonectomy emphyema: the case of fenestration. Thorax. 1979;34:740–5. [PMC free article: PMC471187] [PubMed: 542912]
374.
Dartevelle P, Khalife J. Surgical approach to local recurrence and the second primary lesion. In: Delarue NC, Eschapasse H, editors. Lung cancer. Toronto, Canada: WB Saunders; 1985. p.156-63.
375.
Weisel RD, Cooper JD, Delarue NC. et al. Sleeve lobectomy for carcinoma of the lung. J Thorac Cardiovasc Surg. 1979;78:839–49. [PubMed: 228125]
376.
Faber LP. Sleeve resections for lung cancer. J Thorac Cardiovasc Surg. 1993;5:238–45. [PubMed: 8353151]
377.
Tedder M, Anstadt MP, Tedder SD. et al. Current morbidity, mortality and survival after bronchoplastic procedures for malignancy. Ann Thorac Surg. 1992;54:387–91. [PubMed: 1637243]
378.
Frist WH, Mathisen DJ, Hilgenberg AD. et al. Tracheal sleeve resection with and without pulmonay resection. J Thorac Cardiovasc Surg. 1987;93:350–4. [PubMed: 3821144]
379.
Naruke T. Bronchoplastic and bronchovascular procedures of the tracheobronchial tree in the management of primary lung cancer. Chest. 1989;96:53S–55S. [PubMed: 2661170]
380.
Perleman MI. Lumpectomy for lung cancer. Chest. 1986;89:336S–337S.
381.
Fell SC, Kirby TJ, Limited pulmonary resection. In: Pearson FG, Cooper JD, Deslaruriers J, Ginsberg RJ, Hiebert CA, Patterson GA, Urshel Jr., JC, (eds.), Thoracic Surgery, 2nd edition. New York/Churchill Livingston, Chap. 36, pg. 991–1001, 2002.
382.
Ginsberg RJ, Rubenstein LA. A randomized comparative trial of lobectomy versus limited resection for patients with T1N0 non-small cell lung cancer. Lung Cancer. 1991;7:83–8.
383.
Jensik RJ. Extent of resection for localized lung cancer: segmental resection. In: Kittle CF, editor. Current controversies in thoracic surgery. Philadelphia/Saunders, 1986. p. 175-82.
384.
Paone JF, Spees EK, Newton CG. et al. An appraisal of en bloc resection of peripheral bronchogenic carcinoma involving the thoracic wall. Chest. 1982;81:203–10. [PubMed: 7056085]
385.
Martini N. Surgical treatment of non-small cell lung cancer by stage. Semin Surg Oncol. 1990;6:248–51. [PubMed: 2173095]
386.
Patterson GA, Ives R, Ginsberg RJ. et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann Thorac Surg. 1982;34:692–7. [PubMed: 7149847]
387.
Cromartie R, Parker E, May J. et al. Carcinoma of the lung: a clinical review. Ann Thorac Surg. 1980;30:30–5. [PubMed: 7396575]
388.
Pearson FG. Carinal resection: colon overview. In: Motta G, editor. Staging and treatment. Lung cancer frontiers in science and treatment. Geneoa, Italy: Grafica, LP; 1945. p. 389-92.
389.
Kamb A, Shattuck-Eidens D, Liu Q. et al. Analysis of the p16 gene (CDKN2) as a candidate from chromosome 9p melanoma susceptibility locus. Nature Genet. 1994;8:22–6. [PubMed: 7987388]
390.
Dartevelle PG, Chapelier AR, Pastorino U. et al. Long-term follow-up after prosthetic replacement of the superior vena cava combined with resection of mediastinal-pulmonary malignant tumors. Ann Thorac Surg. 1991;102:259–65. [PubMed: 1865699]
391.
Nakahara K, Ohno K, Matsumura A. Extended operation for lung cancer invading the aortic arch and superior vena cava. J Thorac Cardiovasc Surg. 1993;97:428–33. [PubMed: 2918738]
392.
Ferguson MK, DeMeester TR, Deslauriers J. et al. Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg. 1985;89:378–85. [PubMed: 3974273]
393.
Ferguson MK. Synchronous primary lung cancers. Chest. 1993;103S:398s–401s. [PubMed: 8462333]
394.
Christensen ES. Diagnosis and treatment of bilateral primary bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1971;61:501–4. [PubMed: 5549106]
395.
Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606–11. [PubMed: 170482]
396.
Deschamps C, Pairolero PC, Trastek VF. et al. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg. 1990;99:769–78. [PubMed: 2329815]
397.
Deslauriers J, Brisson J, Cartier R. et al. Carcinoma of the lung: evaluation of satellite nodules as a factor influencing prognosis after resection. J Thorac Cardiovasc Surg. 1989;97:504–12. [PubMed: 2927156]
398.
DeMeester TR. The staging issue: unification of criteria; discussion. In: Delarue NC, Eschapasse H, editors. Lung cancer. Philadelphia: WB Saunders; 1985. p. 37–41.
399.
Ricci C, Rendina EA, Venuta F. et al. Diagnostic imaging and surgical treament of dumbbell tumors of the mediastinum. Ann Thorac Surg. 1990;50:586–9. [PubMed: 2222047]
400.
Shields TW. Multiple primary bronchial carcinomas. Ann Thorac Surg. 1979;27:1–6. [PubMed: 453952]
401.
Van Bodegom PC, Wagenaar SS, Corrin B. et al. Second primary lung cancer: importance of long-term follow-up. Thorax. 1989;44:788–93. [PMC free article: PMC1020843] [PubMed: 2595619]
402.
Green N, Kern W. The clinical course and treatment results of patients with postresection locally recurrent lung cancer. Cancer. 1978;42:2478–82. [PubMed: 214222]
403.
Mountain CF, Libshitz HI, Hermes KE. Lung cancer: a handbook for staging and imaging. In: Mountain CF, editor. Lung cancer: a handbook for staging and imaging. Houston, TX: Charles P. Young Co; 1992. p. 37–62.
404.
Rocmans P. Surgery in non-small cell lung cancer. J Belge Radiol. 1985;68:217–20. [PubMed: 2999065]
405.
Martini N, Flehinger BJ, Zaman MB. et al. Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg. 1980;80:390–9. [PubMed: 6251316]
406.
Thomas PA, Piantadosi S, Mountain CF. Should subcarinal lymph nodes be routinely examined in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 1988;95:883–7. [PubMed: 2834610]
407.
Stanford W, Barnes RP, Tucker AR. Influence of staging in superior sulcus (Pancoast) tumors of the lung. Ann Thorac Surg. 1980;29:406–10. [PubMed: 7377881]
408.
Bergh NP, Schersten T. Bronchogenic carcinoma. A follow-up study of a surgically treated series with special reference to the prognostic significance of lymph node metastases. Acta Chir Hung. 1965;347:1–42.
409.
Larsson S. Pretreatment classification and staging of bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg. 1973;10:1–6.
410.
Mountain CF. Expanded possibilities for surgical treatment of lung cancer. Survival in stage III-a disease. Chest. 1990;97:1045–51. [PubMed: 2158877]
411.
Soorae AS, Stevenson HM. Survival with residual tumor on a bronchial margin after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1979;78:175–80. [PubMed: 459524]
412.
Shields TW. The fate of patients after incomplete resection of bronchial carcinoma. Surg Gynecol Obstet. 1974;139:569–72. [PubMed: 4138454]
413.
Kaiser LR, Fleshner P, Keller S. et al. The significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg. 1989;47:265–9. [PubMed: 2537610]
414.
Mountain CF. Lung cancer staging classification. Lung Cancer. 1993;14:43–53. [PubMed: 8462247]
415.
Higashiyama M, Doi O, Kodama K. et al. Surgical treatment of adrenal metastases following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy. Int.Surg. 1994;79:124–9. [PubMed: 7523325]
416.
Kirsch AJ, Oz MC, Stoopler M. et al. Operative management of adrenal metastases from lung carcinoma. Urology. 1993;42:716–9. [PubMed: 8256407]
417.
Putnam JB Jr, Walsh GL, Swisher SG. et al. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. Ann Thorac Surg. 2000;69:369–75. [PubMed: 10735665]
418.
Tyldesley S, Boyd C, Schulze K. et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001;49:973–85. [PubMed: 11240238]
419.
Bach PB, Cramer LD, Schrag D. et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med. 2001;345:181–8. [PubMed: 11463014]
420.
Lee JS, Scott CB, Komaki R. et al. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:362–70. [PubMed: 11872281]
421.
Giraud P, Grahek D, Montravers F. et al. CT and F-18-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys. 2001;49:1249–57. [PubMed: 11286831]
422.
Vanuytsel LJ, Vansteenkiste JF, Stroobants SG. et al. The impact of F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–24. [PubMed: 10869746]
423.
Seltzer MA, Yap CS, Silverman DH. et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002;43:752–6. [PubMed: 12050318]
424.
Caldwell CB, Mah K, Ung YC. et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of (18)FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–31. [PubMed: 11704312]
425.
MacManus MP, Hicks RJ, Matthews JP. et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical therapy. Int J Radiat Oncol Biol Phys. 2001;50:287–93. [PubMed: 11380213]
426.
Erdi YE, Rosenzweig K, Erdi AK. et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET) Radiother Oncol. 2002;62:51–60. [PubMed: 11830312]
427.
Mac Manus MP, Wong K, Hicks RJ. et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002;52:351–61. [PubMed: 11872280]
428.
Giraud P, Antoine M, Larrouy A. et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys. 2000;48:1015–24. [PubMed: 11072158]
429.
Stevens CW, Munden RF, Forster KM. et al. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys. 2001;51:62–8. [PubMed: 11516852]
430.
Ramsey CR, Scaperoth D, Arwood D. et al. Clinical efficacy of respiratory gated conformal radiation therapy. Medical Dosimetry. 1999;24:115–9. [PubMed: 10379508]
431.
Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys. 2001;49:199–204. [PubMed: 11163515]
432.
Rosenzweig KE, Hanley J, Mah D. et al. The deep inspiration breath-hold technique in the treatment of inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;48:81–7. [PubMed: 10924975]
433.
Akhurst T, Downey RJ, Ginsberg MS. et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;73:259–64. [PubMed: 11834020]
434.
Wang L, Yorke E, Desobry G. et al. Dosimetric advantage of using 6 MV over 15 MV photons in conformal therapy of lung cancer: Monte Carlo Studies in patient geometries. J Appl Clin Med Phys. 2002;3:51–9. [PubMed: 11818004]
435.
Walsh GL, Pisters KM, Stevens C. Treatment of stage I lung cancer. Chest Surg Clin N Am 2001;11:17–38, vii. [PubMed: 11253597]
436.
Kupelian PA, Komaki R, Allen P. Treatment of node negative nonsmall cell lung cancer with radiation therapy alone. Int J Radiat Oncol Biol Phys. 1996;36:607–13. [PubMed: 8948345]
437.
McGarry RC, Song GB, des Rosiers P. et al. Observation-only management of early stage, medically inoperable lung cancer—poor outcome. Chest. 2002;121:1155–8. [PubMed: 11948046]
438.
Hayakawa K, Mitsuhashi N, Katano S. et al. High-dose radiation therapy for elderly patients with inoperable or unresectable non-small cell lung cancer. Lung Cancer. 2001;32:81–8. [PubMed: 11282432]
439.
Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest. 1995;108:1278–82. [PubMed: 7587429]
440.
Langer CJ. Elderly patients with lung cancer: biases and evidence. Curr Treat Opt Oncol. 2002;3:85–102. [PubMed: 12057091]
441.
Martini N, Beattie EJ. Results of surgical treatment in stage I lung cancer. J Thorac Cardiovasc Surg. 1977;74:499–505. [PubMed: 904349]
442.
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615–22. [PubMed: 7677489]
443.
Hilton GL. Present position relating to cancer of the lung: results with radiation therapy alone. Thorax. 1960;15:17–8. [PubMed: 14401832]
444.
Smart J. Can lung cancer be cured by radiation therapy alone? JAMA. 1966;195:158–9.
445.
Dosoretz D, Galmarini D, Rubenstein J. et al. Local control in medical inoperable lung cancer and analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys. 1993;27:507–16. [PubMed: 8226142]
446.
Fujiwara T, Mukhopadhyay T, Cai DW. et al. Retroviral-mediated transduction of p53 gene increases TGF-α expression in a human glioblastoma cell line. Int J Cancer. 1994;56:834–9. [PubMed: 8119773]
447.
Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1–2N0) non-small cell lung cancer. Radiother Oncol. 1996;41:41–4. [PubMed: 8961366]
448.
Morita K, Fuwa N, Suzuki Y. et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol. 1997;42:31–6. [PubMed: 9132823]
449.
Jeremic B, Shibamoto Y, Milicic B. et al. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys. 1998;40:343–6. [PubMed: 9457819]
450.
Hayman JA, Martel MK, Ten Haken RK. et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001;19:127–36. [PubMed: 11134205]
451.
Zierhut D, Bettscheider C, Schubert K. et al. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC) Lung Cancer. 2001;3:S39–S43. [PubMed: 11740992]
452.
Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56:628–38. [PMC free article: PMC1746110] [PubMed: 11462066]
453.
Uematsu M, Shioda A, Suda A. et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys. 2001;51:666–70. [PubMed: 11597807]
454.
Wulf J, Hadinger U, Oppitz U. et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlentherapie und Onkologie. 2001;177:645–55. [PubMed: 11789403]
455.
Rosenzweig KE, Sim SE, Mychalczak B. et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:681–5. [PubMed: 11395236]
456.
Pisters KM, Kris MG, Bunn PAJ. et al. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Bimodality Lung Oncology Team. Sem Oncol. 1997;24:S12–S41. [PubMed: 9331120]
457.
Rice TW, Adelstein DJ, Koka A. et al. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg. 1995;60:586–91. [PubMed: 7677484]
458.
Cai J, Chu JC, Recine D. et al. CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching method. Int J Radiat Oncol Biol Phys. 1999;43:883–91. [PubMed: 10098445]
459.
Port Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet. 1998;352:257–263. [PubMed: 9690404]
460.
Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med. 1986;315:1377–81. [PubMed: 2877397]
461.
Ginsberg RJ. Multimodality therapy for stage IIIA (N2) lung cancer. An overview. Chest. 1993;103:356S–359S. [PubMed: 8384970]
462.
Martini N, McCaughan B, Bains MS. et al. Improved survival in resection for selected stage III lung cancer. Lung Cancer. 1986;2:97–102.
463.
Mountain CF. Surgery for stage IIIA (N2) for nonsmall cell lung cancer. Cancer. 1994;73:2589–2598. [PubMed: 8174057]
464.
Rosell R, Gomez-Condina J, Camps C. et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–8. [PubMed: 8043059]
465.
Roth JA, Fossella F, Komaki R. et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–80. [PubMed: 8158698]
466.
Keller SM, Adak S, Wagner H. et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med. 2000;343:1217–22. [PubMed: 11071672]
467.
Emami B, Kaiser L, Simpson J. et al. Postoperative radiation therapy in non-small cell lung cancer. Am J Clin Oncol. 1997;20:441–8. [PubMed: 9345326]
468.
Holmes E, Bleehen N, Lechevalier T. Postoperative adjuvant treatments for non-small cell lung cancer: a consensus report. Lung Cancer. 1991;7:3–11.
469.
Perez CA, Bauer M, Edelstein S. et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation [published erratum appears in Int J Radiat Oncol Biol Phys 1986 Nov;12:2057] Int J Radiat Oncol Biol Phys. 1986;12:539–47. [PubMed: 3009368]
470.
Dillman RO, Seagren SL, Propert KJ. et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–5. [PubMed: 2169587]
471.
Dillman RO, Herndon J, Seagren SL. et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–5. [PubMed: 8780630]
472.
Le Chevalier T, Brisgand D, Douillard JY. et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients [see comments] J Clin Oncol. 1994;12:360–7. [PubMed: 8113844]
473.
Schaake-Koning C, van den BW, Dalesio O. et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–30. [PubMed: 1310160]
474.
Sause WT, Scott C, Taylor S. et al. Radiation therapy oncology group (RTOG) 88-08 and eastern cooperative oncology group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205. [PubMed: 7707407]
475.
Sause W, Kolesar P, Taylor S IV. et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64. [PubMed: 10669675]
476.
Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis [see comments] Cancer. 1995;76:593–601. [PubMed: 8625152]
477.
Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer—a meta-analysis. Ann Intern Med. 1996;125:723–729. [PubMed: 8929005]
478.
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br Med J. 1995;311:899–909. [PMC free article: PMC2550915] [PubMed: 7580546]
479.
American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol. 1997;15:2996–3018. [PubMed: 9256144]
480.
Socinski MA, Rosenman JG, Schell MJ. et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma—a modified phase I trial. Cancer. 2000;89:534–42. [PubMed: 10931452]
481.
Byhardt RW, Scott C, Sause WT. et al. Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998;42:469–78. [PubMed: 9806503]
482.
Komaki R, Roth JA, Walsh GL. et al. Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M.D. Anderson Cancer Center. Intl J Rad Oncol Biol Phys. 2000;48:347–54. [PubMed: 10974447]
483.
Robertson JM, Ten Haken RK, Hazuka MB. et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1079–85. [PubMed: 9169816]
484.
Oetzel D, Schraube P, Hensley F. et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 1995;33:455–60. [PubMed: 7673033]
485.
Graham MV, Jain NL, Kahn MG. et al. Evaluation of an objective plan-evaluation model in the three-dimensional treatment of nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1996;34:469–74. [PubMed: 8567350]
486.
Maguire PD, Sibley GS, Zhou SM. et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999;45:97–103. [PubMed: 10477012]
487.
Mehta MP. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine [review] [11 refs] Semin Radiat Oncol. 1998;8(Suppl 6):14–16. [PubMed: 9794996]
488.
Antonadou D, Coliarakis N, Synodinou M. et al. The clinical radiation oncology Hellenic group. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–22. [PubMed: 11704311]
489.
Komaki R, Lee JS, Kaplan B. et al. Randomized phase III study chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Sem Radiat Oncol. 2002;12:46–9. [PubMed: 11917284]
490.
Beach P, Siebeneck B, Budereer NF. et al. Relationship between fatigue and nutritional status in patients receiving radiation therapy to treat lung cancer. Oncol Nurs For. 2001;28:1027–31. [PubMed: 11475876]
491.
McQuellon RP, Moose DB, Russell GB. et al. Supportive use of megestrol acetate (megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52:1180–5. [PubMed: 11955728]
492.
Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984;2:961–9. [PubMed: 6205125]
493.
Fincher RE. Superior vena cava syndrome: experience in teaching hospital. South Med J. 1987;80:1243–5. [PubMed: 3660040]
494.
Parish JM, Marschke RF, Dines DE. et al. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc. 1981;56:407–13. [PubMed: 7253702]
495.
Banker VP, Maddision FE. Superior vena cava syndrome secondary to aortic disease: a report of two cases and review of the literature. Dis Chest. 1967;51:656–62. [PubMed: 6027039]
496.
Kamiya K, Nahata Y, Naiki K. et al. Superior vena cava syndrome. Vasc Dis. 1967;4:59–65. [PubMed: 6019433]
497.
Lockridge SK, Knibbe WP, Doty DB. Obstruction of the superior vena cava. Surgery. 1979;85:14–24. [PubMed: 758711]
498.
Escalante CP. Causes and management of superior vena cava syndrome. Oncology. 1993;7:61–8. [PubMed: 8318360]
499.
Millar J, Ball D, Worotniuk V. et al. Radiation treatment of superior sulcus lung carcinoma. Australasian Radiology. 1996;40:55–60. [PubMed: 8838890]
500.
Dartevelle PG, Chapelier AR, Macchiarini P. et al. Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. J Thorac Cardiovasc Surg. 1993;105:1025–34. [PubMed: 8080467]
501.
York JE, Walsh GL, Lang FF. et al. Combined chest wall resection with vertebrectomy and spinal reconstruction for the treatment of pancoast tumors. J Neurosurg. 1999;91:74–80. [PubMed: 10419372]
502.
Paulson DL. Carcinomas in the superior pulmonary sulcus. J Thorac Cardiovasc Surg. 1975;70:1095–104. [PubMed: 1186286]
503.
Fuller DB, Chambers JS. Superior sulcus tumors: combined modality. Ann Thorac Surg. 1994;57:1133–9. [PubMed: 8179375]
504.
Komaki R, Mountain CF, Holbert JM. et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (MO) at presentation. Int J Radiat Oncol Biol Phys. 1990;19:31–6. [PubMed: 2380092]
505.
Wright CD, Menard MT, Wain JC. et al. Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus. Ann Thorac Surg. 2002;73:1541–4. [PubMed: 12022546]
506.
Rusch VW, Giroux DJ, Kraut MJ. et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results fo southwest oncology group trial 9416 (intergroup trial 0160) J Thorac Cardiovasc Surg. 2001;121:472–83. [PubMed: 11241082]
507.
Carrel T, Nachbur B, Bleher A. Is radiotherapy prior to surgical resection indicated for bronchogenic carcinoma with chest wall infiltation and for pancoast tumors? Lung Cancer. 1988;4:A80–A81.
508.
Rice TW, Pringle JF, Sinclair JE. et al. Superior sulcus tumours—results of treatment. Lung Cancer. 1986;2:156–63.
509.
Paulson DL. Technical considerations in stage III disease: the “superior sulcus” lesion. In: Delarue NC, Eschapasse H, editors. International trends in general surgery. Philadelphia: WB Saunders; 1985. p. 121-31.
510.
Beyer DC, Weisenburger T. Superior sulcus tumors. Am J Clin Oncol. 1986;9:156–63. [PubMed: 3087154]
511.
Ricci C, Rendina EA, Venuta F. Surgical treatment of superior sulcus tumors. Lung Cancer. 1988;4:A95–A96.
512.
Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol. 1986;4:1598–603. [PubMed: 3772415]
513.
Shahian DM, Neptune WB, Ellis FH Jr. Pancoast tumors: improved survival with preoperative and postoperative radiotherapy. Ann Thorac Surg. 1987;43:32–8. [PubMed: 3800479]
514.
Komaki R, Roh J, Cox JD. et al. Superior sulcus tumors: results of irradiation of 36 patients. Cancer. 1981;48:1563–9. [PubMed: 7284959]
515.
van Houtte P, MacLennan I, Poulter C. et al. External radiation in the management of superior sulcus tumor. Cancer. 1984;54:223–8. [PubMed: 6202389]
516.
Schray MF, McDougall JC, Martinez A. et al. Management of malignant airway compromise with laser and low dose rate brachytherapy. Chest. 1988;93:264–9. [PubMed: 2448089]
517.
Roach M, Leidholdt EM, Tater BS. et al. Endobronchial radiation therapy in the management of lung cancer. Int J Radiat Oncol Biol Phys. 1990;18:1449–54. [PubMed: 1695216]
518.
Allen MD, Baldwin JC, Fish VJ. et al. Combined laser therapy and endobronchial radiotherapy for unresectable lung carcinoma with bronchial obstruction. Am J Surg. 1985;150:71–7. [PubMed: 2409829]
519.
Mehta MP, Shababi S, Jarjour NN. et al. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys. 1989;17:847–51. [PubMed: 2777675]
520.
Perol M, Caliandro R, Pommier P. et al. Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy. Results of a pilot study. Chest. 1997;111:1417–23. [PubMed: 9149603]
521.
Tredaniel J, Hennequin C, Zalcman G. et al. Prolonged survival after high-dose rate endobronchial radiation for malignant airway obstruction. Chest. 1994;105:767–72. [PubMed: 7510599]
522.
Hilaris BS, Nori D, Martini N. Intraoperative radiotherapy in stage I and II lung cancer. Semin Surg Oncol. 1987;3:22–32. [PubMed: 3027826]
523.
Nori D, Li X, Pugkhem T. Intraoperative brachytherapy using Gelfoam radioactive plaque implants for resected stage III non-small cell lung cancer with positive margin: a pilot study. J Surg Oncol. 1995;60:257–61. [PubMed: 8551736]
524.
Chen A, Galloway M, Landreneau R. et al. Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int.J.Radiat.Oncol.Biol.Phys. 1999;44:1057–63. [PubMed: 10421539]
525.
Lee JS, Komaki R, Morice RC. et al. A pilot clinical laboratory trial of paclitaxel and endobronchial brachytherapy in patients with non-small cell lung cancer. Semin Radiat Oncol. 1999;9:121–9. [PubMed: 10210551]
526.
Langendijk H, de Jong J, Tjwa M. et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol. 2001;58:257–68. [PubMed: 11230886]
527.
Delclos ME, Komaki R, Morice RC. et al. Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions. Radiology. 1996;201:279–82. [PubMed: 8816560]
528.
Cotter GW, Herbert DE, Ellingwood KE. Inoperable endobronchial obstructing lung carcinoma treated with combined endobronchial and external beam irradiation. Southern Med J. 1991;84:562–5. [PubMed: 2035073]
529.
Gollins SW, Burt PA, Barber PV. et al. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol. 1994;33:31–40. [PubMed: 7533304]
530.
Bedwinek J, Petty A, Bruton C. et al. The use of HDR endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Semin Surg Oncol. 1992;22:23–30. [PubMed: 1727125]
531.
Hara R, Itami J, Aruga T. et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer. 2001;92:2623–7. [PubMed: 11745197]
532.
Bonnet RB, Bush D, Cheek GA. et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small-cell lung cancer. Chest. 2001;120:1803–10. [PubMed: 11742905]
533.
Chen Y, Pandya K, Keng PPFR. et al. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol. 2001;24:432–7. [PubMed: 11586091]
534.
Stevens CW, Lee JS, Cox J. et al. Novel approaches to locally advanced unresectable non-small cell lung cancer. Radiother Oncol. 2000;55:11–8. [PubMed: 10788683]
535.
Johnson DH. Chemotherapy for unresectable non-small cell lung cancer. Semin Oncol. 1990;7:20–4. [PubMed: 2166346]
536.
Ihde DC. Chemotherapy of lung cancer. N Engl J Med. 1992;327:1434–9. [PubMed: 1328881]
537.
Negoro S, Fukuoka M, Masuda N. et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Inst. 1991;83:1164–70. [PubMed: 1653362]
538.
Fukoka M, Niitani H, Suzuki A. et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol. 1992;10:16–21. [PubMed: 1309380]
539.
Fossella FV, Lee JS, Murphy WK. et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238–44. [PubMed: 7911160]
540.
Cerny T, Kaplan S, Pavlidis N. et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG) Br J Cancer. 1994;70:384–9. [PMC free article: PMC2033518] [PubMed: 7914429]
541.
Alberti W, Anderson G, Bartolucci A. et al. Chemotherapy in non-small cell lung cancer: a meta- analysis using updated data on individual patients from 52 randomised clinical trials. Br Med Bull. 1995;311:899–909. [PMC free article: PMC2550915] [PubMed: 7580546]
542.
Murphy WK, Fossella FV, Winn RJ. et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:384–8. [PubMed: 8094466]
543.
Chung AY, Kim K, Glick J. et al. Phase I study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst. 1993;85:388–91. [PubMed: 8094467]
544.
Gatzemeier U, Pawel JV, Heckmayer M. et al. Phase II study with paclitaxel in advanced inoperable NSCLC—the European experience. Lung Cancer. 1995;12(Suppl):S101–S106. [PubMed: 7551941]
545.
Anderson H, Lund B, Bach F. et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1821–6. [PubMed: 8083706]
546.
Abratt RP, Bezwoda WR, Falkson G. et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer. J Clin Oncol. 1994;12:1535–41. [PubMed: 8040664]
547.
Depierre A, Lemarie E, Dabouis G. et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol. 1991;14:115–9. [PubMed: 1851385]
548.
Le Chevalier T. Gemcitabine and pemetrexed (alimta) in thoracic cancers: present and future perspectives. Introduction and current controversies. Semin Oncol. 2002;29:43–6. [PubMed: 12094338]
549.
Lynch TJ, Kalish L, Strauss G. et al. Phase II study of topotecan in metastatic non-small cell lung cancer. J Clin Oncol. 1994;12:347–52. [PubMed: 8113842]
550.
Perez-Soler R, Glisson BS, Lee JS. et al. Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc Am Soc Clin Oncol. 1995;14:355–60.
551.
Sandler AB, Nemunaitis J, Denham C. et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000;18:122–30. [PubMed: 10623702]
552.
Klastersky J. Therapy with cisplatin and etoposide for non-small cell lung cancer. Semin Oncol. 1986;13:104–9. [PubMed: 3020693]
553.
Bunn PA. The expanding role of cisplatin in the treatment of non-small cell lung cancer. Semin Oncol. 1989;16:10–6. [PubMed: 2548280]
554.
Takasugi BJ, Miller TP. Chemotherapy of advanced non-small cell lung cancer. Invest New Drugs. 1984;2:339–41. [PubMed: 6392149]
555.
Schiller JH, Harrington D, Belani CP. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8. [PubMed: 11784875]
556.
Elliott JA, Ahmedzal S, Hole D. et al. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol. 1984;20:1025–30. [PubMed: 6540685]
557.
Einhorn LH, Loehrer PJ, Williams SD. et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitromycin C in advanced non-small-cell lung cancer. J Clin Oncol. 1986;4:1037–41. [PubMed: 3088219]
558.
Kubota K, Nakai R, Ogawa M. et al. A randomized study of cisplatin (CDDP) versus DPP plus vindesine in advanced non-small cell lung cancer with an analysis of prognostic factors using multivariate methods. Lung Cancer. 1988;4:A125–A126.
559.
Klastersky J, Sculier JP, Bureau G. et al. For the Lung Cancer Working Party (Belgium): cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol. 1989;7:1087–92. [PubMed: 2547028]
560.
Rosso R, Salvati F, Ardizzoni A. et al. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: results of a prospective randomized FONICAP trial. Cancer. 1990;65:130–2. [PubMed: 2162239]
561.
von Pawel J, von Roemeling R, Gatzemeier U. et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol. 2000;18:1351–9. [PubMed: 10715308]
562.
Rapp E, Pater JL, Willan A. et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol. 1988;6:633–9. [PubMed: 2833577]
563.
Quoix E, Dietemann A, Charbonneau J. et al. La chimiotherapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Resultats d'une etude randomisee. Cancer Bull. 1991;78:341–5. [PubMed: 1650266]
564.
Kaasa S, Lund E, Thorud E. et al. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer. 1991;67:2443–9. [PubMed: 1849786]
565.
Cellerino R, Tummarello D, Guidi F. et al. A randomized trail of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol. 1991;9:1453–9. [PubMed: 1649267]
566.
Ganz PA, Figlin RA, Haskell CM. et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Cancer. 1989;63:1271–5. [PubMed: 2465815]
567.
Woods RL, Williams CJ, Levi J. et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990;61:608–11. [PMC free article: PMC1971367] [PubMed: 1691921]
568.
Cormier Y, Bergeron D, La Forge J. et al. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer. 1982;50:845–51. [PubMed: 7093924]
569.
Buccheri G, Ferrigno D, Rosso A. et al. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer. 1990;6:87–94.
570.
Cartei G, Cartei F, Cantone A. et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst. 1993;85:794–800. [PubMed: 8387607]
571.
Ranson M, Davidson N, Nicolson M. et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:1074–80. [PubMed: 10880550]
572.
The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999;91:66–72. [PubMed: 9890172]
573.
Jaakkimainen L, Goodwin P, Pater J. et al. Counting the costs of chemotherapy in a National Cancer Institute randomized trial in non-small cell lung cancer. J Clin Oncol. 1990;8:1301–5. [PubMed: 2166142]
574.
Wozniak AJ, Crowley JJ, Balcerzak SP. et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study [see comments] J Clin Oncol. 1998;16:2459–65. [PubMed: 9667264]
575.
Bonomi P, Kim KM, Fairclough D. et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial. J Clin Oncol. 2000;18:623–31. [PubMed: 10653877]
576.
Giaccone G, Splinter TAW, Debruyne C. et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:2133–41. [PubMed: 9626213]
577.
Choy H, Shyr Y, Cmelak AJ. et al. Patterns of practice survey for nonsmall cell lung carcinoma in the US. Cancer. 2000;88:1336–46. [PubMed: 10717614]
578.
Langer CJ, Leighton JC, Comis RL. et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860–70. [PubMed: 7543559]
579.
Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung ancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 17, 455a. 1998.
580.
Kelly K, Crowley J, Bunn PA Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8. [PubMed: 11432888]
581.
Crino L, Scagliotti GV, Ricci S. et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian lung cancer project. J Clin Oncol. 1999;17:3522–30. [PubMed: 10550150]
582.
Cardenal F, Lopez-Cabrerizo MP, Anton A. et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12–8. [PubMed: 10458212]
583.
Thatcher N, Jayson G, Bradley B. et al. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer [review]. [37 refs] Sem Oncol. 1997;24(Suppl):S8. [PubMed: 9207309]
584.
Georgoulias V, Papadakis E, Alexopoulos A. et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478–84. [PubMed: 11377599]
585.
Masuda N, Fukuoka M, Negoro S. et al. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus (CPT-11) alone in advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol. 1999;18:459a.
586.
Fossella FV, Millward M, Bosquee L, et al. Docetaxel + Cisplatin (DC) and Docetaxel + Carboplatin (DCb) vs Vinorelbine + Cisplatin (VC) in chemotherapy-naïve patients with advanced and metastatic non-small lung cancer (NSCLC): results of a multicenter, randomized phase III study. Proc 12th Int Congr Anti Cancer Treat, p. 123, 2002.
587.
Kunitoh H, Nishiwaki Y, Noda K. Phase III randomized trial to compare survival, antitumor response, and tolerability between docetaxel/cisplatin and the standard Japanese regimen (in 1988). Vindesine/cisplatin, in advanced NSCLC [abstract] Proc Am Soc Clin Oncol. 2001;20:323a.
588.
Socinski MA, Schell MJ, Peterman A. et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002;20:1335–43. [PubMed: 11870177]
589.
Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol. 1997;24:455–62. [PubMed: 9280225]
590.
Fossella FV. Docetaxel for previously trated non-small cell lung cancer. Oncology. 2002;16:45–51. [PubMed: 12108897]
591.
Fossella FV, DeVore R, Kerr RN. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX320 non small cell lung cancer study group. J Clin Oncol. 2000;18:2354–62. [PubMed: 10856094]
592.
Shepherd FA, Dancey J, Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103. [PubMed: 10811675]
593.
Shields TW, Robinette CD, Keehn RJ. Bronchiocarcinoma treated by adjuvant cancer chemotherapy. Arch Surg. 1974;109:329–31. [PubMed: 4367749]
594.
Shields TW, Higgins GA Jr, Humphrey EW. et al. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer. 1982;50:1713–21. [PubMed: 6749280]
595.
Scott H, Stephens WF, Roy DC. Five year follow up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br J Cancer 1976;167-72. [PMC free article: PMC2025161] [PubMed: 786362]
596.
Feld R, Rubinstein L, Thomas PA. et al. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. J Natl Cancer Inst. 1993;85:299–306. [PubMed: 8381187]
597.
Niiranen A, Niitamokorhonen S, Kouri M. et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. J Clin Oncol. 1992;10:1927–32. [PubMed: 1333518]
598.
Ichinose Y, Hara N, Ohta M. et al. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and postrecurrent survival. J Surg Oncol. 1991;46:15–21. [PubMed: 1702493]
599.
Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J. 2000;113:617–20. [PubMed: 11776031]
600.
Wada H, Miyahara R, Tanaka F. et al. Postoperative adjuvant chemotherapy with PVM (Cisplatin plus Vindesine plus Mitomycin C) and UFT (Uracil plus Tegaful) in resected stage I-II NSCLC (non-small-cell lung cancer): a randomized clinical trial. Eur J CardioThoracic Surg. 1999;15:438–43. [PubMed: 10371118]
601.
Wada H, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy for non-small-cell lung cancer. Oncology. 1997;11:98–102. [PubMed: 9348578]
602.
Holmes EC, Gail M. Lung Cancer Study Group. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986;4:710–5. [PubMed: 3009726]
603.
Lad T, Rubinstein L, Sadeghi A. The Lung Cancer Study Group: The benefits of adjuvant treatment for resected locally advanced non-small cell lung cancer. J Clin Oncol. 1988;6:9–14. [PubMed: 2891798]
604.
Goldie JH, Coldman AJ. A mathematical model for relating sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–34. [PubMed: 526911]
605.
Pisters KMW, Ginsberg RJ, Giroux DJ. et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg. 2000;119:429–39. [PubMed: 10694600]
606.
Depierre A, Milleron B, Moro-Sibilot D. et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–53. [PubMed: 11773176]
607.
Le Chevalier T, Arriagada R, Quoix E. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–23. [PubMed: 1847977]
608.
Le Chevalier T, Arriagada R, Tarayre M. et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcnoma [letter-comment] J Natl Cancer Inst. 1992;84:58. [PubMed: 1310747]
609.
Kubota K, Furuse K, Kawahara M. et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol. 1994;12:1547–52. [PubMed: 8040666]
610.
Jeremic B, Shibamoto Y, Acimovic L. et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995;13:452–8. [PubMed: 7844608]
611.
Furuse K, Fukuoka M, Kawahara M. et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9. [PubMed: 10561343]
612.
Curran WJ. Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC) initial report of radiation therapy oncology group (RTOG) 9410 [abstract] Proc Am Soc Clin Oncol. 2000;19:1891a.
613.
Belani CP, Ramanathan RK. Combined-modality treatment of locally advanced non-small cell lung cancer—incorporation of novel chemotherapeutic agents. Chest. 1998;113:53S–60S. [PubMed: 9438691]
614.
Choy H, Akerley W, Safran H. et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:3316–22. [PubMed: 9779707]
615.
Langer CJ, Movsas B, Hudes R. et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001. Semin Oncol. 1997;24(Suppl):S12–95. [PubMed: 9331129]
616.
Vokes EE, Herndon JE, Crawford J. et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191–8. [PubMed: 12377962]
617.
Gandara D. Pathological stage IIIb non-small-cell lung cancer (NSCLC): prolonged survival with consolidation of docetaxel following concurrent chemo-radiotherapy (SWOG 9504) [abstract] Lung Cancer. 2000;29(Suppl 1):92.
618.
Matthews MJ, Kanhouwa S, Pickren J. et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep. 1973;4:63–7. [PubMed: 4580861]
619.
Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep. 1973;4:31–2. [PubMed: 4580860]
620.
Fox W, Scadding JG. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Lancet. 1973;2:63–5. [PubMed: 4123619]
621.
Higgins GA, Shields TW, Keehn RJ. The solitary pulmonry nodule: ten-year follow-up of Veterans Administration-Armed Forces cooperative study. Arch Surg. 1975;110:570–7. [PubMed: 1093512]
622.
Green RA, Humphrey E, Close H. et al. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969;46:516–22. [PubMed: 5791000]
623.
Higgins BA. Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma. Cancer. 1972;30:1383–7. [PubMed: 4343295]
624.
Shields TW, Humphrey EW, Eastridge CE. et al. Adjuvant cancer chemotherapy after resection of carcinoma of the lung. Cancer. 1977;40:2057–66. [PubMed: 336178]
625.
Karrer K, Pridun N, Denck H. Chemotherapy as an adjuvant to surgery in lung cancer. Cancer Chemother. Pharmacol. 1978;1:145–7. [PubMed: 219964]
626.
Bunn PA, Ihde DC. Small cell bronchogenic carcinoma: a review of therapeutic results. In: Livingston RB, editor. lung Cancer. The Hague: Martinus Nijhoff; 1981. p. 169–208.
627.
Kreisman H, Wolkove N, Quoix E. Small-cell lung-cancer presenting as a solitary pulmonary nodule. Chest. 1992;101:225–31. [PubMed: 1309497]
628.
Quoix E, Fraser R, Wolkove N. et al. Small-cell lung-cancer presenting as a solitary pulmonary nodule. Cancer. 1990;66:577–82. [PubMed: 2163746]
629.
Shepherd FA, Ginsberg RJ, Feld R. et al. Surgical treatment for limited small-cell lung cancer. J Thorac Cardiovasc Surg. 1991;101:385–93. [PubMed: 1847981]
630.
Ginsberg RJ. Surgery and small cell lung cancer—an overview. Lung Cancer. 1989;5:232–6.
631.
Warren WH, Faber LP, Gould VE. Neuro-endocrine neoplasms of the lung—a clinicopathologic update. J Thoracic Cardiovascular Surgery. 1989;98:321–32. [PubMed: 2549306]
632.
Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–5. [PubMed: 1316951]
633.
Pignon J-P, Arriagada R, Ihde DC. et al. A meta-analysis of thoracic radiotheapy for small cell lung cancer. N Engl J Med. 1992;327:1618–24. [PubMed: 1331787]
634.
Looney WB. The experimental basis of new strategies in combining chemotherapy and radiotherapy. In: Horwich A, editor. Combined radiotherapy and chemotherapy in clinical oncology. London: Edward Arnold; 1992. p. 23–33.
635.
Arriagada R, Pellae-Cosset B, Cueto Ladron de Guevara J. et al. Alternating radiotherapy and chemotherapy schedules in limited small cell lung cancer: analysis of local chest recurrences. Radiother Oncol. 1991;20:91–8. [PubMed: 1851572]
636.
Arriagada R, Le Chevalier T, Pignon J-P. et al. Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med. 1993;329:1848–52. [PubMed: 8247036]
637.
McCracken JD, Janaki LM, Crowley JJ. et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group study. J Clin Oncol. 1990;8:892–8. [PubMed: 2159055]
638.
Janaki L, Rector D, Turrisi A. et al. Patterns of failure and second malignancies from SWOG-8629: concurrent cisplatin, etoposide, vincristine, and once daily radiotherapy for the treatment of limited small cell lung cancer [abstrac] Proc Am Soc Clin Oncol. 1994;13:331–2.
639.
Turrisi AT III. Current perspectives in the treatment of small cell lung cancer. Lung Cancer. 1993;9:S109–S117.
640.
Johnson BE, Salem C, Nesbitt J. et al. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin. Lung Cancer. 1993;9:S21–S26.
641.
Komaki R, Shin DM, Glisson BS. et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys. 1995;31:807–11. [PubMed: 7860392]
642.
Murray N, Coy P, Pater JL. et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small cell lung cancer. J Clin Oncol. 1993;11:336–44. [PubMed: 8381164]
643.
Wagner H, Kim K, Johnson DH. et al. Daily vs twice-daily thoracic irradiation with concurrent cisplatin/etoposide chemotherapy as initial therapy for patients with limited small cell lung cancer: preliminary results of a phase III prospective intergroup trial. Int J Radiat Oncol Biol Phys. 1994;30:178–80.
644.
Turrisi AT, Kim K, Blum R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71. [PubMed: 9920950]
645.
Cox JD. Dose response in small cell carcinoma [editorial] Int J Radiat Oncol Biol Phys. 1988;14:393–4. [PubMed: 2828291]
646.
Coy P, Hodson I, Payne DG. et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian multicenter randomized trial. Int J Radiat Oncol Biol Phys. 1988;14:219–26. [PubMed: 2828289]
647.
Arriagada R, Le Chevalier T, Ruffie P. et al. Alternating radiotherapy and chemotherapy in 173 consecutive patients with limited small cell lung carcinoma. GROP and the French Cancer Center's Lung Group. Int J Radiat Oncol Biol Phys. 1990;19:1135–8. [PubMed: 2174838]
648.
Choi NC, Herndon J, Rosenman J. et al. Phase I study to determine the maximum tolerated dose of radiation in standard franctionated and accelerated twice daily radiation schedules with concurrent chemotherapy for limited stage small cell lung cancer (CALGB 8837) Int J Radiat Oncol Biol Phys. 1994;30:179–83. [PubMed: 9817271]
649.
Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep. 1981;65:811–4. [PubMed: 6268295]
650.
Bunn PA, Nugent JL, Matthews MJ. Central nervous system metastases in small cell bronchogenic carcinoma. Semin Oncol. 1978;5:314–20. [PubMed: 211643]
651.
Hirsch FR, Paulson OB, Hansen HH. et al. Intracranial metastases in small cell carcinoma of the lung: correlation of clinical and autopsy findings. Cancer. 1982;50:2433–9. [PubMed: 6182974]
652.
Hansen HH. Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation? Cancer Chemother Rep. 1973;4:239–41. [PubMed: 4354042]
653.
Bleehen NM, Bunn PA, Cox JD. et al. Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1983;67:11–9. [PubMed: 6193877]
654.
Krauss S, Lowenbraun S, Bartolucci A. et al. Alternating non-cross resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung. Cancer Clin Trials. 1981;4:147–50. [PubMed: 6265109]
655.
Cox JD, Petrovich Z, Paig C. et al. Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung: preliminary report of a cooperative trial. Cancer. 1978;42:1135–40. [PubMed: 212171]
656.
Hansen HH, Dombernowsky P, Hirsch FR. et al. Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma: a comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer. 1980;46:279–82. [PubMed: 6992979]
657.
Aroney RS, Aisner J, Wesley MN. et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep. 1983;67:675–82. [PubMed: 6307516]
658.
Seydel HG, Creech R, Pagano M. et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol. 1985;8:218–22. [PubMed: 2996327]
659.
Arriagada R, Le Chevalier T, Borie F. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87:183–7. [PubMed: 7707405]
660.
Mattson K, Niiranen A, Holsti L. et al. Low-dose natural alpha interferon as maintenance therapy for small cell lung cancer. A phase II study. Proc Am Soc Clin Oncol. 1989;8:227–8.
661.
Lee JS, Umsawasdi T, Lee YY. et al. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys. 1986;12:313–6. [PubMed: 3007407]
662.
Komaki R, Byhardt RW, Anderson T. et al. What is the lowest effective biologic dose for prophylactic cranial irradiation? Am J Clin Oncol. 1985;8:523–7. [PubMed: 4083270]
663.
Komaki R, Meyers CA, Shin DM. et al. Evaluation of cognitive function in patients with limited small-cell lung-cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179–82. [PubMed: 7642416]
664.
Auperin A, Arriagada R, Pignon JP. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476–84. [PubMed: 10441603]
665.
Hansen HH, Dombernowsky P, Hansen M. Chemotherapy of advanced small cell anaplastic carcinoma: superiority of a four-drug combination to a three-drug combination. Ann Intern Med. 1978;89:633–8. [PubMed: 209710]
666.
Jett JR, Everson L, Therneau TM. et al. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized study of the North Central Cancer Treatment Group. J Clin Oncol. 1990;8:33–9. [PubMed: 2153193]
667.
Johnson D. New drugs in the management of small cell lung cancer. Lung Cancer. 1989;5:221–5.
668.
Smit EF, Carney DN, Hartford P. et al. A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax. 1989;44:631–4. [PMC free article: PMC461991] [PubMed: 2477908]
669.
Einhorn L, Pennington K, McClean J. Phase II trail of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol. 1990;17:32–4. [PubMed: 2154857]
670.
Mead GM, Thompson J, Sweetenham JW. et al. Extensive stage small cell carcinoma of the bronchus: a randomized study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide. Cancer Chemother Pharmacol. 1987;19:172–4. [PubMed: 3032470]
671.
Miller AA, Herndon JE, Hollis DR. et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer—a randomized phase-III study of the Cancer and Leukemia Group-B. J Clin Oncol. 1995;13:1871–9. [PubMed: 7636529]
672.
Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinetics. 1987;12:223–9. [PubMed: 3297462]
673.
Aisner J, Alberto P, Bitran J. et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer Workshop. Cancer Treat Rep. 1983;67:37–41. [PubMed: 6311413]
674.
Batist G, Carney DN, Cowan KH. et al. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinicial trial and in vitro correlates. J Clin Oncol. 1986;4:982–8. [PubMed: 3012008]
675.
Giaccone G, Donadio M, Bonardi G. et al. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–300. [PubMed: 2842464]
676.
Aisner J. Identification of new drugs in small cell lung cancer: phase II agents first? Cancer Treat Rep. 1987;71:1131–5. [PubMed: 2825989]
677.
Cullen MH, Hilton C, Stuart NSA. Evaluating new drugs as first treatment in patients with small cell carcinoma: guidelines for an ethical approach with implications for other chemotherapy-sensitive tumors. J Clin Oncol. 1988;6:1356–60. [PubMed: 2842466]
678.
Ettinger DS. Evaluation of new drugs in untreated patients with small cell lung cancer: its time has come. J Clin Oncol. 1990;8:374–81. [PubMed: 2155306]
679.
Grant SC, Gralla RJ, Kris MG. et al. Single-agent chemotherapy trials in small cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol. 1992;10:484–90. [PubMed: 1311028]
680.
Moore TD, Korn EL. Phase II trial design considerations for small cell lung cancer. J Natl Cancer Inst. 1992;85:150–6. [PubMed: 1311772]
681.
Ettinger DS, Finkelstein DM, Abeloff MD. et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive stage small cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992;84:1077–82. [PubMed: 1320131]
682.
Edmonson JH, Lagakos SW, Selawry OS. et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma of the lung. Cancer Treat Rep. 1976;60:925–30. [PubMed: 1009523]
683.
Lowenbraun S, Bartolucci A, Smalley RV. et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 1979;44:406–12. [PubMed: 224997]
684.
Alberto P, Brunner KW, Martz G. et al. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine. Cancer. 1976;38:2208–14. [PubMed: 187313]
685.
Johnson DH, Einhorn LH, Birch R. A randomized comparison of high-dose versus convential-dose cyclophosphamide, doxorubicin and vincristine for extensive-stage small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987;5:1731–7. [PubMed: 2824707]
686.
Figueredo AT, Hryniuk WM, Strautmanis I. et al. Cotrimoxazole prophylaxis during high dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985;3:54–7. [PubMed: 2981292]
687.
Johnson DH. Recent developments in chemotherapy treatment of small cell lung cancer. Semin Oncol. 1993;20:315–9. [PubMed: 8393591]
688.
Jackson DV, Case LD, Zekan PJ. et al. Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol. 1988;6:1161–8. [PubMed: 2839632]
689.
Lowenbraun S, Birch R, Buchanan R. et al. Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens. Cancer. 1984;54:2344–61. [PubMed: 6093979]
690.
Messieh AA, Schweitzer JM, Lipson A. et al. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep. 1987;71:61–7. [PubMed: 3024828]
691.
Roth BJ, Johnson DH, Einhorn LH. et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–9. [PubMed: 1310103]
692.
Hong WK, Nicaise C, Larson R. et al. Etopoise combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol. 1989;7:450–61. [PubMed: 2538577]
693.
Hirsch FR, Hansen HH, Hansen M. et al. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol. 1987;5:585–91. [PubMed: 3031225]
694.
Smith IE, Evans BD, Harland SJ. et al. High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma. Cancer Chemother Pharmacol. 1985;14:120–4. [PubMed: 2982509]
695.
Loehrer PJ, Einhorn LH, Greco FA. Cisplatin plus etoposide in small cell lung cancer. Sem Oncol. 1988;5:2–10. [PubMed: 2839902]
696.
Evans WK, Osoba D, Feld R. et al. Etoposide and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol. 1985;3:65–71. [PubMed: 2981293]
697.
Sierocki JS, Hilaris BS, Hopfan S. et al. Cis-dichlorodiamineplatinum (II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep. 1979;63:1593–7. [PubMed: 227598]
698.
Evans WK, Shepherd FA, Osoba D. et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;5:1471–2. [PubMed: 2997406]
699.
Boni C, Cocconi G, Bisagni G. et al. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. Cancer. 1989;63:638–44. [PubMed: 2536584]
700.
Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;855-61. [PubMed: 1648142]
701.
Einhorn LH, Crawford J, Birch R. et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. J Clin Oncol. 1988;6:451–6. [PubMed: 2832549]
702.
Noda K, Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin compared with etoposide plus cisplating for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91. [PubMed: 11784874]
703.
Sculier JP, Klastersky J, Libert P. et al. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer [letter] Eur J Cancer. 1990;26:919–21. [PubMed: 2171602]
704.
Shepherd FA, Evans WK, MacCormick R. et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treatment. Rep. 1987;71:941–4. [PubMed: 2820571]
705.
Johnson DH, Greco FA, Strupp J. et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990;8:1613–7. [PubMed: 2170589]
706.
von Pawel J, Schiller JH, Shepherd FA. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–67. [PubMed: 10080612]
707.
Masuda N, Fukuoka M. Irinotecan in the treatment of small cell lung cancer. Epert Rev Anticancer Ther. 2001;1:187–195. [PubMed: 12113024]
708.
Schabel FM, Griswold DP, Korbett TH, et al. Testing therapeutic hypothesis in mice and man: observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumor of man. In: DeVita VT, Busch H, editors. Cancer drug development. New York: Academic Press; 1979. p. 3.
709.
Cohen MH, Creaven PJ, Fossieck BE Jr. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977;61:349–54. [PubMed: 194691]
710.
Mehta C, Vogl SE. High-dose cyclophosphamide in the induction chemotherapy of small cell lung cancer—minor improvements in rate of remission and survival [abstract] Proc Am Assoc Cancer Res. 1982;23:155–6.
711.
Hande KR, Oldham RK, Fer MF. et al. Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer. Am J Med. 1982;73:413–20. [PubMed: 6289661]
712.
Ihde DC, Mulshine JL, Kramer BS. et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022–8. [PubMed: 7931470]
713.
Borg C, Ligneau B, Trillet-Lenoir V. Dose intensity of chemotherapy in small-cell lung carcinoma. Bulletin du Cancer. 2001;88:863–70. [PubMed: 11604359]
714.
Abeloff MD, Ettinger DS, Order SE. et al. Intensive induction chemotherapy in 54 patients with small cell carcinoma of the lung. Cancer Treat Rep. 1981;65:639–44. [PubMed: 6265082]
715.
Brower M, Ihde DC, Johnson-Early A. Treatment of extensive stage small cell bronchogenic carcinoma. Effects of variation in intensity of induction chemotherapy. Am J Med. 1983;75:993–1002. [PubMed: 6316784]
716.
Valdivieso M, Cabanillas F, Kearting M. Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment prophylactic antibiotic units. Am J Med. 1984;76:405–8. [PubMed: 6322584]
717.
Markman M, Abeloff MD, Berkman AW. et al. Intensive alternating chemotherapy regimen in small cell carcinoma of the lung. Cancer Treat Rep. 1985;69:161–7. [PubMed: 2982490]
718.
Johnson DH, DeLeo MJ, Hande KR. et al. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. J Clin Oncol. 1987;5:703–10. [PubMed: 3033161]
719.
Farha P, Spitzer G, Valdivisso M. et al. High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small cell lung carcinoma. Cancer. 1983;52:1351–8. [PubMed: 6311392]
720.
Harper PG, Souhami RL. Intensive chemotherapy with autologous bone marrow transplantation in small cell carcinoma of the lung. Recent Results Cancer Res. 1985;97:146–56. [PubMed: 2986241]
721.
Stewart P, Buckner CD, Thomas ED. et al. Intensive chemotherapy with autologous marrow transplantation for small cell carcinoma of the lung. Cancer Treat Rep. 1983;67:1055–60. [PubMed: 6317175]
722.
Spitzer G, Farha P, Valdivieso M. et al. High-dose intensificatino therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol. 1986;4:4–11. [PubMed: 3510281]
723.
Humblet Y, Symann M, Bosly A. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol. 1987;5:1864–71. [PubMed: 2824708]
724.
Sculier JP, Klastersky J, Strychkamans P. et al. Late intensification in small cell lung cancer: a phase I study of high doese of cyclophosphamide and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1985;3:184–9. [PubMed: 2981983]
725.
Klasa RJ, Murray N, Coldman AJ. Dose-intensity metaanalysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9:499–508. [PubMed: 1847968]
726.
Elias AD, Ayash L, Frei E III. et al. Intensive combined modality therapy for limited-stage small-cell lung cancer. J Natl Cancer Inst. 1993;85:559–62. [PubMed: 8384264]
727.
Ardizzoni A, Tjan-Heijnen V, Postmus P. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer—Lung Cancer Group phase III trial—08923. J Clin Oncol. 2002;20:3947–55. [PubMed: 12351591]
728.
Galani E, Ellis PA, Harper PG. Small-cell lung cancer, high growth rate, high response rate to chemotherapy: ideal for high-dose chemotherapy? J Clin Oncol. 2002;20:3941–9. [PubMed: 12351589]
729.
Taylor CW, Crowley J, Williamson SK. et al. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study. J Clin Oncol. 1990;8:1811–6. [PubMed: 2172473]
730.
Miles DW, Earl HM, Souhami RL. et al. Intensive weekly chemotherapy for good prognosis patients with small-cell lung cancer. J Clin Oncol. 1991;9:280–4. [PubMed: 1846406]
731.
Murray N, Shah A, Osoba D. et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 1991;9:1632–8. [PubMed: 1651995]
732.
Souhami R, Rudd R, Ruiz de Elvira MC. et al. Randomized tiral comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol. 1994;12:1806–10. [PubMed: 8083704]
733.
Sculier JP, Paesmans M, Bureau G. et al. Multi-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol. 1993;11:1858–61. [PubMed: 8410110]
734.
Miles DW, Fogarty O, Ash CM. et al. Reveived dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol. 1994;12:77–81. [PubMed: 7505809]
735.
Goldie JH, Coldman AJ. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep. 1982;66:439–41. [PubMed: 7060033]
736.
Cohen MH, Ihde DC, Bunn PA. et al. Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep. 1979;62:163–8. [PubMed: 221114]
737.
Evans WK, Feld R, Murray N. et al. Superiority of alternating noncross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med. 1987;107:451–5. [PubMed: 2820289]
738.
Goodman GE, Crowley JJ, Blasko JC. et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicine, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J Clin Oncol. 1990;8:39–44. [PubMed: 2153194]
739.
Wampler GL, Heim WJ, Ellison NM. et al. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung caricnoma: a Mid-Atlantic Oncology Program study. J Clin Oncol. 1991;9:1438–42. [PubMed: 1649265]
740.
Ettinger DS, Finkelstein DM, Aberloff MD. et al. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive non-small cell lung cancer: a phase II study of the Eastern Cooperative Oncology Group. J Clin Oncol. 1990;8:230–6. [PubMed: 2153765]
741.
Feld R, Evans WK, Coy P. et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987;5:1401–9. [PubMed: 3040923]
742.
Wolf M, Pritsch M, Drings P. et al. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients. J Clin Oncol. 1991;9:614–21. [PubMed: 1648598]
743.
Bleehan NM, Fayers PM, Girling DJ. et al. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer. 1989;59:584–90. [PMC free article: PMC2247128] [PubMed: 2540789]
744.
Spiro SG, Souhami RL, Geddes DM. et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989;59:578–81. [PMC free article: PMC2247136] [PubMed: 2540788]
745.
Maurer LH, Tulloh M, Weiss RB. A randomized combined modality trial in small cell carcinoma of the lung. Cancer. 1980;45:30–4. [PubMed: 6243242]
746.
Giaccone G, Dalesio O, McVie GJ. et al. Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial. J Clin Oncol. 1993;11:1230–5. [PubMed: 8391065]
747.
Cullen M, Morgan D, Gregory W. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized controlled trial. Cancer Chemother Pharmacol. 1986;17:157–9. [PubMed: 3013442]
748.
Byrne MJ, Van Hazel G, Troter J. et al. Maintenance chemotherapy in limited small cell lung cancer: a randomized controlled clinical trial. Br J Cancer. 1989;60:413–21. [PMC free article: PMC2247200] [PubMed: 2551359]
749.
Dombernowsky P, Hansen HH. Combination chemotherapy in the management of superior vena cava obstruction in small-cell anaplastic carcinoma of the lung. Acta Med Scand. 1978;204:513–8. [PubMed: 216239]
750.
Spiro SG, Shah S, Harper PG. et al. Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus. Thorax. 1983;38:501–9. [PMC free article: PMC459595] [PubMed: 6310812]
751.
Lee JS, Murphy WK, Glisson BS. et al. Primary chemotherapy of brain metastasis in small-cell lung. J Clin Oncol. 1989;7:916–21. [PubMed: 2544685]
752.
Mattson K, Niiranen A, Pyrhonen S. et al. Natural interferon-α as maintenance therapy for small cell lung cancer. Eur J Cancer. 1992;28A:1387–94. [PubMed: 1325176]
753.
Postmus PE, Smit EF, Haaxma-Reiche H. et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study. J Clin Oncol. 1983;51:933–8.
754.
Giaccone G, Donadio M, Bonardi GM. et al. Tenoposide: an effective treatment for brain metastases of small cell carcinoma of the lung. Eur J Cancer Clin Oncol. 1988;24:629–31. [PubMed: 2838291]
755.
Van Hazel G, Scott M, Eagan RT. The effect of CNS metastases on the survival of patients with small cell cancer of the lung. Cancer. 1983;51:933–9. [PubMed: 6295619]
756.
Hirsch FR, Paulson OB, Hansen HH. et al. Intracranial metastases in small cell-carcinoma of the lung—prognostic aspects. Cancer. 1983;51:529–33. [PubMed: 6295606]
757.
Giaccone L, Johnson DH, Hande KR. et al. Favorable prognosis of brain metastases in small cell lung cancer. Ann Intern Med. 1987;106:386–91. [PubMed: 3028222]
758.
Brown CC, Kessler LG. Projections of lung cancer mortality in the United States: 1985-2025. J Natl Cancer Inst. 1988;80:43–51. [PubMed: 3339638]
759.
Miller DL, McManus KG, Allen MS. et al. Results of surgical resection in patients with N2 non-small-cell lung cancer. Ann Thorac Surg. 1994;57:1095–100. [PubMed: 8179370]
760.
Ishida I, Tateishi M, Kaneko S. Surgical treatment of patients with nonsmall cell lung cancer and mediastinal lymph node involvements. J Surg Oncol. 1990;43:161–6. [PubMed: 2156111]
761.
Frytak S, Eagan RT, Sawanua K. et al. Treatment of “limited” stage III non-small-cell carcinoma of the lung. Cancer Invest. 1988;6:193–207. [PubMed: 2837315]
762.
Martini N, Flehinger BJ, Zaman MB. et al. Results of resection in non-oat-cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg. 1983;198:386–97. [PMC free article: PMC1353314] [PubMed: 6615059]
763.
Ginsberg RJ, Martini N, Zaman M. et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg. 1994;57:1440–5. [PubMed: 8010786]
764.
Maggi G, Casadio C, Pischedda F. et al. Combined radiosurgical treatment of pancoast tumor. Ann Thorac Surg. 1994;57:198–202. [PubMed: 8279890]
765.
Mill JL, Shanian DM, Neptune WB. et al. Pancoast tumors: improved survival with preopertive and postoperative radiotherapy. Ann Thorac Surg. 1987;43:32–8. [PubMed: 3800479]
766.
Harpole DHJ, Healey EA, DeCamp MMJ. et al. Chest wall invasive non-small-cell lung cancer: patterns of failure and implications for a revised staging system. Ann Surg Oncol. 1996;3:261–9. [PubMed: 8726181]
767.
Martinez-Monge R, Herreros J, Aristu JJ. Combined treatment in superior sulcus tumors. Am J Clin Oncol. 1994;17:317–22. [PubMed: 8048394]
768.
Gatzemeier U, von Pawel J, Gottfried M. et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:3390–9. [PubMed: 11013280]
769.
Ratto GB, Piacenza G, Frola C. et al. Chest wall involvement by lung cancer; computed tomographic detection and results of operation. Ann Thorac Surg. 1991;51:182–87. [PubMed: 1846522]

By agreement with the publisher, this book is accessible by the search feature, but cannot be browsed.

Copyright © 2003, BC Decker Inc.
Bookshelf ID: NBK12945

Views

  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...